CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11991033,1199103312,12,F,,20200610,20160202,20200622,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200622,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1199103312,OT,,,,,,,,,1199103312,1,HIV infection
12741534,127415345,5,F,,20200601,20160914,20200606,EXP,,CA-ROCHE-1829817,ROCHE,,,,,M,Y,,,20200606,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,127415345,OT,,,,,,,,,127415345,1,Product used for unknown indication
12781371,127813717,7,F,20160901,20200424,20160926,20200508,EXP,,US-ACTELION-A-US2016-142509,ACTELION,,58,YR,,M,Y,,,20200508,,MD,US,US,SUSTIVA,Abdominal pain;Alanine aminotransferase increased;Ascites;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Blood bilirubin increased;Cardiac failure;Chills;Cholecystitis;Cholelithiasis;Chromaturia;Feeling abnormal;Hepatic pain;Hyponatraemia;International normalised ratio increased;Jaundice;Liver function test abnormal;Nausea;Portal vein pressure increased;Pyrexia,127813717,OT,,,127813717,1,20160319,,,,127813717,1,Pulmonary arterial hypertension
12985056,129850565,5,F,,20200528,20161129,20200605,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20200605,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,129850565,OT,,,,,,,,,129850565,1,HIV infection
13851390,138513903,3,F,,20200610,20170809,20200622,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-069840,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200622,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,138513903,OT,,,,,,,,,138513903,1,HIV infection
14649319,146493193,3,F,,20200528,20180316,20200603,EXP,,CA-APOTEX-2018AP006359,APOTEX,,45,YR,,M,Y,,,20200603,,CN,CA,CA,EFAVIRENZ.,Multiple-drug resistance,146493193,OT,,,,,,,,,146493193,1,HIV infection
14652614,146526144,4,F,,20200601,20180319,20200608,EXP,,CA-APOTEX-2018AP007741,APOTEX,,44,YR,,M,Y,,,20200608,,CN,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146526144,HO,,,,,,,,,146526144,1,Psychotic disorder
14682623,146826235,5,F,20180313,20200514,20180327,20200521,EXP,,ZA-AUROBINDO-AUR-APL-2018-015610,AUROBINDO,,35,YR,,F,Y,,,20200521,,HP,ZA,ZA,EFAVIRENZ.,Cardiac murmur;Maternal exposure during pregnancy,146826235,OT,,,146826235,1,20180214,,,,146826235,1,HIV infection
14819352,148193522,2,F,20180423,20200508,20180427,20200523,EXP,,UG-CIPLA LTD.-2018UG17107,CIPLA,,,,,,Y,,,20200523,,HP,UG,UG,EFAVIRENZ.,Pneumocystis jirovecii pneumonia,148193522,HO,,,148193522,1,20180421,20180423,,,148193522,1,Meningitis cryptococcal
14931261,149312616,6,F,,20200612,20180524,20200618,EXP,,CA-ROCHE-2126762,ROCHE,,52,YR,,M,Y,,,20200618,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,149312616,OT,,,,,,,,,149312616,1,HIV infection
14942273,149422736,6,F,20180430,20200508,20180528,20200523,EXP,,UG-CIPLA LTD.-2018UG18131,CIPLA,,,,,,Y,,,20200523,,HP,UG,UG,EFAVIRENZ.,Anaemia;Genital lesion;Hypomagnesaemia;Hypoproteinaemia;International normalised ratio increased;Myelitis transverse;Urinary tract infection,149422736,OT,,,149422736,1,20180420,20180420,,,149422736,1,Meningitis cryptococcal
15095440,150954406,6,F,20171006,20200601,20180702,20200603,EXP,,GB-GILEAD-2018-0347475,GILEAD,,43,YR,A,F,Y,,,20200603,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150954406,OT,,,150954406,1,20171006,20180205,,,150954406,1,HIV infection
15112110,151121105,5,F,20171006,20200601,20180705,20200603,EXP,,GB-GILEAD-2018-0347708,GILEAD,,,,N,M,Y,,,20200603,,MD,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,151121105,CA,,,151121105,1,20171006,20180205,,,151121105,1,HIV infection
15123625,1512362525,25,F,20180205,20200527,20180710,20200605,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20200605,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,1512362525,OT,,,1512362525,1,20171006,20180205,,,1512362525,1,HIV infection
15158165,1515816511,11,F,20171006,20200527,20180718,20200604,EXP,,GB-AUROBINDO-AUR-APL-2018-036078,AUROBINDO,,43,YR,,F,Y,,,20200605,,CN,GB,GB,Efavirenz Film-coated Tablet,Abortion spontaneous;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy,1515816511,OT,,,1515816511,1,20171006,,,,1515816511,1,HIV infection
15248149,152481498,8,F,20050813,20200414,20180807,20200420,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002639",BOEHRINGER INGELHEIM,,25,YR,,F,Y,56,KG,20200420,,MD,FR,FR,SUSTIVA,Abortion induced;Insomnia;Maternal exposure during pregnancy;Vertigo,152481498,HO,,,152481498,1,20050620,20050908,,,152481498,1,HIV infection
15249829,152498295,5,F,20060216,20200409,20180807,20200409,EXP,,FR-ABBVIE-18S-056-2444229-00,ABBVIE,,25,YR,,F,Y,56,KG,20200409,,HP,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,152498295,HO,,,152498295,1,20050908,20050908,,,152498295,1,HIV infection
15302247,153022477,7,F,2014,20200608,20180821,20200610,EXP,,ES-PFIZER INC-2018330979,PFIZER,"BRAVO, I.. RECURRENT CORONARY DISEASE IN HIV-INFECTED PATIENTS: ROLE OF DRUG-DRUG INTERACTIONS.. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2018;84 (7):1617-1619",39,YR,,M,Y,,,20200610,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Drug interaction;Vascular stent thrombosis,153022477,HO,,,153022477,1,2014,,,,153022477,3,Antiplatelet therapy
15308899,153088993,3,F,2014,20200608,20180823,20200616,EXP,,ES-MACLEODS PHARMACEUTICALS US LTD-MAC2018015707,MACLEODS,,,,,,Y,,,20200616,,CN,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,153088993,OT,,,153088993,1,2012,,,,153088993,1,HIV infection
15357443,153574437,7,F,20171005,20200527,20180906,20200608,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-NOVOPROD-619477,NOVO NORDISK,,43,YR,,F,Y,,,20200608,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Intentional product use issue,153574437,OT,,,153574437,2,20171006,20180205,,,153574437,1,Product used for unknown indication
15357909,153579099,9,F,20171006,20200429,20180906,20200504,EXP,GB-AUROBINDO-AUR-APL-2018-033634,PHHY2018GB086977,NOVARTIS,,43,YR,,F,Y,,,20200504,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy,153579099,OT,,,153579099,2,20171006,20180205,,,153579099,1,Product used for unknown indication
15448433,154484333,3,F,,20200407,20180929,20200416,EXP,,PT-AUROBINDO-AUR-APL-2018-047799,AUROBINDO,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A.. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C.. INTERVIROLOGY. 2018;1-8",32,YR,,M,Y,,,20200416,,HP,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154484333,LT,,,,,,,,,154484333,1,Hepatitis C
15473306,154733066,6,F,,20200417,20181008,20200421,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-089598,BRISTOL MYERS SQUIBB,,32,YR,,M,Y,,,20200421,,HP,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154733066,OT,,,,,,,,,154733066,1,Chronic hepatitis C
15559787,155597877,7,F,,20200617,20181029,20200619,EXP,,PHHY2018PT113969,NOVARTIS,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C. INTERVIROLOGY. 2018;1-8",32,YR,,M,Y,,,20200619,,HP,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,155597877,OT,,,,,,,,,155597877,1,HIV infection
15622139,156221392,2,F,2018,20200417,20181115,20200428,EXP,,UG-MYLANLABS-2018M1086991,MYLAN,,,,,F,Y,4.1,KG,20200428,,HP,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221392,OT,,,156221392,1,20180409,,,,156221392,1,Product used for unknown indication
15838467,158384676,6,F,20171006,20200601,20190117,20200602,EXP,,GB-MYLANLABS-2019M1001573,MYLAN,,43,YR,,F,Y,,,20200602,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,158384676,OT,,,158384676,1,20171006,20180205,,,158384676,1,HIV infection
15980310,159803104,4,F,,20190213,20190219,20200615,EXP,,PHHY2019FR036384,NOVARTIS,,37,YR,,F,Y,,,20200615,,HP,FR,FR,SUSTIVA,Headache;Hypertension;Metrorrhagia;Pre-eclampsia,159803104,HO,,,,,,,,,159803104,1,Product used for unknown indication
15985003,159850032,2,F,,20200423,20190220,20200430,EXP,,BW-STRIDES ARCOLAB LIMITED-2019SP001577,STRIDES,,,,,,Y,,,20200430,,HP,BW,BW,EFAVIRENZ.,Arnold-Chiari malformation;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159850032,CA,,,,,,,,,159850032,1,Product used for unknown indication
15985004,159850042,2,F,20181001,20200423,20190220,20200430,EXP,,BW-STRIDES ARCOLAB LIMITED-2019SP001576,STRIDES,,42,YR,,F,Y,,,20200430,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,159850042,OT,,,,,,,,,159850042,1,HIV infection
15989803,159898032,2,F,,20200513,20190221,20200518,EXP,,BW-MYLANLABS-2019M1015918,MYLAN,,,,N,,Y,,,20200518,,HP,BW,BW,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,159898032,CA,,,,,,,,,159898032,1,Product used for unknown indication
15994788,159947882,2,F,20181001,20200423,20190222,20200429,EXP,,BW-HETERO CORPORATE-HET2019BW00182,HETERO,,0,DY,,,Y,,,20200429,,HP,BW,BW,EFAVIRENZ.,Death;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159947882,CA,,,159947882,1,,20181001,,,159947882,1,HIV infection
15998256,159982563,3,F,,20200420,20190223,20200425,EXP,,CA-009507513-1902CAN006457,MERCK,,54,YR,,M,Y,,,20200425,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,159982563,DE,,,,,,,,,159982563,1,HIV infection
16004905,160049052,2,F,20181001,20200423,20190226,20200429,EXP,,BW-HETERO CORPORATE-HET2019BW00183,HETERO,,42,YR,,F,Y,,,20200429,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,160049052,OT,,,,,,,,,160049052,1,HIV infection
16009753,160097536,6,F,20181001,20200504,20190225,20200518,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-017261,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20200518,,MD,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,160097536,OT,,,,,,,,,160097536,1,HIV infection
16020890,1602089010,10,F,,20200415,20190301,20200423,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,,54,YR,,M,Y,,,20200424,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1602089010,OT,,,,,,,,,1602089010,1,HIV infection
16021250,160212502,2,F,,20200423,20190301,20200506,EXP,,BW-CIPLA LTD.-2019BW01100,CIPLA,,,,,,Y,,,20200506,,HP,BW,BW,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,160212502,OT,,,,,,,,,,,
16021279,160212794,4,F,,20200423,20190301,20200506,EXP,,BW-CIPLA LTD.-2019BW01099,CIPLA,,,,,,Y,,,20200506,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,160212794,OT,,,,,,,,,160212794,1,HIV infection
16022383,160223833,3,F,,20200512,20190301,20200520,EXP,,BW-AUROBINDO-AUR-APL-2019-009434,AUROBINDO,,,,,,Y,,,20200520,,MD,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Stillbirth,160223833,DE,,,,,,,,,160223833,1,Product used for unknown indication
16064851,160648517,7,F,2017,20200617,20190312,20200624,EXP,,US-ABBVIE-19K-163-2698768-00,ABBVIE,,71,YR,,M,Y,73.55,KG,20200623,,CN,US,US,SUSTIVA,Axillary mass;Axillary pain;Cataract;Decreased appetite;Erectile dysfunction;Eye pruritus;Foot deformity;Hand deformity;Infection;Infectious thyroiditis;Mobility decreased;Nasopharyngitis;Neoplasm;Neoplasm skin;Pain;Psoriasis;Psoriatic arthropathy;Rhinitis;Skin discolouration;Subcutaneous abscess;Weight increased;Wound secretion,160648517,OT,,,160648517,1,20150504,201901,,,160648517,1,Psoriatic arthropathy
16080755,160807553,3,F,,20200420,20190316,20200428,EXP,,CA-AUROBINDO-AUR-APL-2019-013379,AUROBINDO,,44,YR,,M,Y,,,20200429,,HP,CA,CA,SUSTIVA,Anxiety,160807553,HO,,,,,,,,,160807553,1,Psychotic disorder
16081150,160811507,7,F,,20200618,20190316,20200629,EXP,,CA-AUROBINDO-AUR-APL-2019-013361,AUROBINDO,,54,YR,,M,Y,,,20200629,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,160811507,HO,,,,,,,,,160811507,1,HIV infection
16081155,160811552,2,F,,20200618,20190316,20200626,EXP,,CA-AUROBINDO-AUR-APL-2019-013363,AUROBINDO,,54,YR,,M,Y,,,20200626,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,160811552,OT,,,,,,,,,160811552,1,HIV infection
16213433,162134333,3,F,20161105,20200320,20190418,20200415,EXP,,US-GILEAD-2019-0402857,GILEAD,,38,YR,A,M,Y,95.69,KG,20200415,,CN,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Femur fracture;Hip arthroplasty;Osteomalacia;Osteonecrosis;Pain,162134333,OT,,,162134333,1,201003,201809,,,162134333,1,HIV infection
16258145,162581452,2,F,,20200429,20190430,20200501,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK074257,GLAXOSMITHKLINE,,,,,,Y,,,20200501,,HP,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162581452,OT,,,,,,,,,162581452,1,HIV infection
16258147,162581472,2,F,,20200429,20190430,20200501,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK074257,VIIV,,,,,,Y,,,20200501,,HP,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162581472,CA,,,,,,,,,162581472,1,HIV infection
16272580,162725802,2,F,201811,20200320,20190503,20200409,EXP,,US-GILEAD-2019-0405402,GILEAD,,52,YR,A,M,Y,,,20200409,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Osteopenia;Pain,162725802,OT,,,162725802,1,201109,201812,,,162725802,1,HIV infection
16288958,162889584,4,F,20050813,20200430,20190509,20200508,EXP,,FR-AUROBINDO-AUR-APL-2019-026163,AUROBINDO,,25,YR,,F,Y,,,20200508,,CN,FR,FR,SUSTIVA,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,162889584,OT,,,162889584,1,20050620,20050908,,,162889584,1,HIV infection
16297818,162978186,6,F,20060216,20200413,20190510,20200417,EXP,,FR-ABBVIE-09P-056-0558368-00,ABBVIE,,,,,F,Y,,,20200417,,MD,FR,FR,SUSTIVA,Abortion induced;Anencephaly;Brain herniation;Encephalocele;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,162978186,DE,,,162978186,1,20050908,,,,162978186,1,Maternal exposure timing unspecified
16304383,163043832,2,F,,20200413,20190513,20200417,EXP,,FR-ABBVIE-19S-056-2776233-00,ABBVIE,,,,,,Y,,,20200417,,HP,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,163043832,DE,,,,,,,,,163043832,1,Maternal exposure timing unspecified
16350708,163507082,2,F,201503,20200326,20190524,20200409,EXP,,US-GILEAD-2019-0409332,GILEAD,,44,YR,A,M,Y,,,20200409,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Osteoporosis;Pain;Renal failure;Spinal fracture,163507082,HO,,,163507082,1,2009,2011,,,163507082,1,HIV infection
16360074,163600742,2,F,201103,20200320,20190528,20200408,PER,,US-GILEAD-2019-0409404,GILEAD,,52,YR,A,M,Y,,,20200408,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Foot fracture;Pain,163600742,OT,,,163600742,1,200410,201907,,,163600742,1,HIV infection
16404826,164048262,2,F,,20200622,20190607,20200630,EXP,,PT-MYLANLABS-2019M1053256,MYLAN,,30,YR,,M,Y,,,20200630,,MD,PT,PT,EFAVIRENZ.,Product use in unapproved indication;Seizure,164048262,OT,,,,,,,,,164048262,1,Mycobacterial infection
16425185,164251853,3,F,20140214,20200506,20190613,20200603,PER,,US-GILEAD-2019-0413099,GILEAD,,47,YR,A,M,Y,,,20200603,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Pain;Tooth loss,,,,,164251853,1,20040213,20100708,,,164251853,1,HIV infection
16438510,164385102,2,F,,20200425,20190617,20200508,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106137,VIIV,,,,,M,Y,,,20200508,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,164385102,OT,,,,,,,,,164385102,1,Product used for unknown indication
16438515,164385152,2,F,,20200425,20190617,20200508,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106137,GLAXOSMITHKLINE,,,,,M,Y,,,20200508,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,164385152,OT,,,,,,,,,164385152,1,Product used for unknown indication
16443892,164438922,2,F,,20200529,20190618,20200609,EXP,,CA-AUROBINDO-AUR-APL-2019-033424,AUROBINDO,,44,YR,,M,Y,,,20200609,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,164438922,HO,,,,,,,,,164438922,1,Psychotic disorder
16494843,164948439,9,F,2014,20200402,20190628,20200424,EXP,,US-GILEAD-2019-0415427,GILEAD,,64,YR,A,M,Y,81.25,KG,20200424,,CN,US,US,SUSTIVA,Amnesia;Anal cancer;Anxiety;Arthralgia;Cardiac failure;Colorectal cancer;Diarrhoea;Disturbance in attention;Gait disturbance;Gastrointestinal disorder;HIV-associated neurocognitive disorder;Insomnia;Laboratory test abnormal;Lipids abnormal;Nausea;Neuropathy peripheral;Nightmare;Osteopenia;Pain in extremity;Stevens-Johnson syndrome;T-lymphocyte count decreased;Tinnitus,164948439,OT,,,164948439,3,2004,,,,164948439,1,HIV infection
16536587,165365875,5,F,20050813,20200409,20190706,20200416,EXP,,FR-AUROBINDO-AUR-APL-2019-038824,AUROBINDO,,,,N,F,Y,1.96,KG,20200416,,CN,FR,FR,EFAVIRENZ.;SUSTIVA,Anencephaly;Arnold-Chiari malformation;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Foetal malformation;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,165365875,CA,,,165365875,1,20050704,20050908,,,165365875,1,HIV infection
16543052,165430523,3,F,,20200618,20190709,20200629,EXP,,CA-AUROBINDO-AUR-APL-2019-037770,AUROBINDO,,,,,M,Y,,,20200629,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,165430523,OT,,,,,,,,,165430523,1,Product used for unknown indication
16583628,165836283,3,F,,20200424,20190717,20200502,EXP,,PT-AUROBINDO-AUR-APL-2018-058733,AUROBINDO,,32,YR,,M,Y,,,20200502,,HP,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis;Transaminases increased,165836283,LT,,,,,,,,,165836283,1,Chronic hepatitis C
16590194,165901945,5,F,,20200616,20190718,20200624,EXP,,CA-TEVA-2018-CA-968075,TEVA,,44,YR,,M,Y,,,20200624,,HP,CA,CA,SUSTIVA,Anxiety,165901945,HO,,,,,,,,,165901945,1,HIV infection
16634649,166346492,2,F,20181001,20200423,20190726,20200429,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022219,MACLEODS,,,,,,Y,,,20200429,,HP,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,166346492,OT,,,,,,,,,166346492,1,HIV infection
16635444,166354442,2,F,,20200423,20190726,20200429,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022220,MACLEODS,,,,,,Y,,,20200429,,HP,US,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,166354442,DE,,,,,,,,,166354442,1,Product used for unknown indication
16635502,166355022,2,F,,20200611,20190726,20200618,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-071705,BRISTOL MYERS SQUIBB,,,,,F,Y,131.54,KG,20200618,,CN,US,US,SUSTIVA,Cardiac disorder;Hypothyroidism;Inappropriate schedule of product administration;Weight increased,166355022,OT,,,,,,,,,166355022,1,Cerebrovascular accident prophylaxis
16647278,166472783,3,F,,20200619,20190730,20200619,EXP,,US-PFIZER INC-2019323656,PFIZER,,73,YR,,F,Y,131.5,KG,20200619,,CN,US,US,SUSTIVA,Cardiac disorder;Hypothyroidism;Inappropriate schedule of product administration;Weight increased,166472783,OT,,,,,,,,,166472783,1,Cerebrovascular accident prophylaxis
16653423,166534232,2,F,2013,20200401,20190731,20200414,EXP,,US-GILEAD-2019-0420315,GILEAD,,,,A,M,Y,,,20200414,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Multiple fractures;Osteonecrosis;Pain;Patella fracture;Tooth loss,166534232,OT,,,166534232,1,20080715,20190215,,,166534232,1,HIV infection
16654245,166542452,2,F,20100326,20200326,20190731,20200414,PER,,US-GILEAD-2019-0420395,GILEAD,,38,YR,A,M,Y,,,20200414,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Pain,,,,,166542452,1,200205,201206,,,166542452,1,HIV infection
16662141,166621417,7,F,201412,20200511,20190802,20200515,EXP,,PHHY2019AT170861,NOVARTIS,,69,YR,,M,Y,90,KG,20200515,,HP,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166621417,OT,,,166621417,1,20031107,20111107,,,166621417,1,Antiretroviral therapy
16676274,166762742,2,F,201701,20200401,20190807,20200416,EXP,,US-GILEAD-2019-0421714,GILEAD,,55,YR,A,M,Y,,,20200416,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Pain;Tooth loss,166762742,OT,,,166762742,1,20090622,20180103,,,166762742,1,HIV infection
16740232,167402322,2,F,,20200610,20190826,20200612,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080274,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200612,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,167402322,OT,,,,,,,,,167402322,1,Product used for unknown indication
16741532,167415324,4,F,,20200610,20190826,20200619,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080379,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20200619,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,167415324,OT,,,,,,,,,167415324,1,HIV infection
16779436,167794362,2,F,20151012,20200320,20190906,20200401,EXP,,US-GILEAD-2019-0426527,GILEAD,,53,YR,A,F,Y,,,20200401,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Pain;Tooth loss,167794362,OT,,,167794362,1,2014,2018,,,167794362,1,HIV infection
16795975,167959753,3,F,1996,20200327,20190911,20200401,EXP,,"ES-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-100655",BOEHRINGER INGELHEIM,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT. CLINICAL DRUG INVESTIGATION. 2019;39:1125-31. DOI:L 0.1007/S40261 -019-00829-X",38,YR,,M,Y,,,20200402,,HP,ES,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,167959753,OT,,,167959753,1,2001,2002,,,167959753,1,Antiretroviral therapy
16800956,168009564,4,F,1996,20200529,20190912,20200602,EXP,,PHHY2019ES207545,NOVARTIS,,38,YR,,M,Y,,,20200602,,HP,ES,ES,EFAVIRENZ.,Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,168009564,OT,,,168009564,11,2001,2001,,,168009564,1,Antiretroviral therapy
16806891,168068918,8,F,2001,20200410,20190913,20200413,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086812,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20200413,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,168068918,OT,,,168068918,1,2001,2001,,,168068918,1,HIV infection
16810112,168101123,3,F,20050822,20200428,20190916,20200601,EXP,,US-GILEAD-2019-0428023,GILEAD,,48,YR,A,M,Y,136.51,KG,20200601,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal failure,168101123,OT,,,168101123,1,200904,201606,,,168101123,1,HIV infection
16859830,168598307,7,F,,20200422,20190927,20200504,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-092601,BRISTOL MYERS SQUIBB,,,,,M,Y,3.23,KG,20200504,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168598307,OT,,,168598307,1,20070403,20070510,,,168598307,1,Product used for unknown indication
16867931,168679313,3,F,1996,20200511,20190930,20200516,EXP,,ES-ROCHE-2412643,ROCHE,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT. CLINICAL DRUG INVESTIGATION 2019;39:1125-1131.",38,YR,,M,Y,,,20200516,,HP,ES,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome;Fatigue;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Neurotoxicity;Pathological fracture;Proteinuria;Renal glycosuria;Renal impairment;Virologic failure,168679313,OT,,,168679313,1,1996,1997,,,168679313,1,Antiretroviral therapy
16912943,169129433,3,F,,20200616,20191014,20200624,EXP,,CA-TEVA-2019-CA-1118733,TEVA,,54,YR,,M,Y,,,20200624,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,169129433,DE,,,,,,,,,169129433,1,Product used for unknown indication
16991906,169919062,2,F,,20200514,20191104,20200522,EXP,,US-ABBVIE-19K-163-2988002-00,ABBVIE,,,,,,Y,,,20200521,,HP,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPRO,Foetal exposure during pregnancy;Hypospadias,169919062,CA,,,,,,,,,169919062,1,Maternal exposure timing unspecified
17023002,170230022,2,F,,20200514,20191112,20200522,EXP,,"ZA-LANNETT COMPANY, INC.-ZA-2019LAN001122",LANNETT,,,,I,,Y,,,20200522,,HP,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPRO,Foetal exposure during pregnancy;Meningomyelocele,170230022,DE,,,,,,,,,170230022,1,Product used for unknown indication
17034605,170346052,2,F,,20200408,20191115,20200417,EXP,,CA-009507513-1911CAN004586,MERCK,,52,YR,,M,Y,,,20200417,,HP,CA,CA,SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,170346052,CA,,,,,,,,,170346052,1,HIV infection
17046127,170461272,2,F,,20200529,20191119,20200606,EXP,,CA-AUROBINDO-AUR-APL-2019-010734,AUROBINDO,,45,YR,,M,Y,,,20200606,,CN,CA,CA,EFAVIRENZ.,Multiple-drug resistance,170461272,OT,,,,,,,,,170461272,1,HIV infection
17075956,170759563,3,F,20031224,20200428,20191126,20200527,EXP,,US-GILEAD-2019-0439500,GILEAD,,63,YR,A,M,Y,,,20200527,,CN,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Foot fracture;Fracture;Hand fracture;Hip fracture;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal failure;Rib fracture,170759563,OT,,,170759563,1,20020730,20050901,,,170759563,1,HIV infection
17075964,170759644,4,F,201009,20200428,20191126,20200527,EXP,,US-GILEAD-2019-0439491,GILEAD,,53,YR,A,M,Y,,,20200527,,CN,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Pain;Renal failure,170759644,OT,,,170759644,1,20020823,20101201,,,170759644,1,HIV infection
17084668,170846682,2,F,20181001,20200423,20191127,20200507,EXP,,"BW-LANNETT COMPANY, INC.-BW-2019LAN001043",LANNETT,,0,DY,,,Y,,,20200507,,HP,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Meningomyelocele;Stillbirth,170846682,OT,,,,,,,,,170846682,1,HIV infection
17129467,171294673,3,F,2012,20200414,20191209,20200417,EXP,,AT-MYLANLABS-2019M1119555,MYLAN,SCHALK H.. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,69,YR,,M,Y,90,KG,20200417,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Cough;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,171294673,OT,,,171294673,1,20040423,201708,,,171294673,1,Antiretroviral therapy
17162493,171624934,4,F,2008,20200429,20191217,20200514,EXP,,US-GILEAD-2019-0442861,GILEAD,,,,A,M,Y,107.03,KG,20200514,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Osteopenia;Pain;Renal failure,171624934,OT,,,171624934,1,200411,20170113,,,171624934,1,HIV infection
17198283,171982832,2,F,,20200409,20191225,20200420,EXP,,CA-ROCHE-2501805,ROCHE,,54,YR,,M,Y,,,20200420,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,171982832,OT,,,,,,,,,171982832,1,Product used for unknown indication
17200991,172009912,2,F,,20200409,20191226,20200417,EXP,,CA-ROCHE-2504996,ROCHE,,54,YR,,M,Y,,,20200417,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,172009912,OT,,,,,,,,,172009912,1,Bipolar disorder
17214260,172142603,3,F,1996,20200617,20191230,20200625,EXP,,ES-MYLANLABS-2019M1127115,MYLAN,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ AC. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT.. CLIN. DRUG INVEST.. 2019;39(11):1125-31",38,YR,,M,Y,,,20200625,,HP,CL,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Bone pain;Chronic kidney disease;Drug abuse;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Intentional product misuse;Lipodystrophy acquired;Medication error;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Nephropathy toxic;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,172142603,OT,,,172142603,1,2002,2011,,,172142603,1,Antiretroviral therapy
17217518,172175182,2,F,201807,20200529,20191231,20200609,EXP,,CA-AUROBINDO-AUR-APL-2019-058844,AUROBINDO,"TSENG AL, ET,AL. DOLUTEGRAVIR/EFAVIRENZ/VALPROIC ACID INTERACTION SUBTHERAPEUTIC DRUG CONCENTRATION: CASE REPORT. REACTIONS WEEKLY. 2019;1767:P124",43,YR,,F,Y,,,20200609,,HP,CA,CA,EFAVIRENZ.,Anticonvulsant drug level below therapeutic;Antiviral drug level below therapeutic;Drug interaction;Drug level below therapeutic;Seizure,172175182,OT,,,172175182,1,2016,,,,172175182,1,HIV infection
17218270,172182704,4,F,20171006,20200527,20191231,20200608,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-EMCURE PHARMACEUTICALS LTD-2018-EPL-0507,EMCURE,,43,YR,,F,Y,,,20200608,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,172182704,OT,,,172182704,3,20171006,20180205,,,172182704,1,Product used for unknown indication
17225079,172250795,5,F,,20200514,20200102,20200520,EXP,,FR-MYLANLABS-2019M1131600,MYLAN,,,,N,M,Y,3.23,KG,20200520,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,172250795,CA,,,172250795,1,20070403,20070521,,,172250795,1,HIV infection
17244332,172443322,2,F,2008,20200403,20200107,20200427,EXP,,US-GILEAD-2019-0444850,GILEAD,,,,A,M,Y,86.17,KG,20200427,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Pain,172443322,OT,,,172443322,1,201002,201204,,,172443322,1,HIV infection
17261505,172615054,4,F,201202,20200429,20200113,20200515,PER,,US-GILEAD-2020-0446114,GILEAD,,43,YR,A,M,Y,81.18,KG,20200515,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Dehydration;Diarrhoea;Economic problem;Emotional distress;Fanconi syndrome acquired;Pain;Pancreatitis;Renal failure;Vomiting,172615054,HO,,,172615054,1,20111010,20120309,,,172615054,1,HIV infection
17303704,173037042,2,F,20170508,20200608,20200122,20200609,EXP,,ZA-GILEAD-2020-0447684,GILEAD,,,,,F,Y,,,20200609,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173037042,OT,,,173037042,1,20170508,,,,173037042,1,HIV infection
17315702,173157022,2,F,,20200528,20200124,20200609,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002860,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200609,,HP,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,173157022,OT,,,,,,,,,173157022,1,Product used for unknown indication
17324001,173240013,3,F,20191211,20200514,20200127,20200529,EXP,,ZA-AUROBINDO-AUR-APL-2020-004158,AUROBINDO,,,,,F,Y,,,20200529,,MD,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173240013,OT,,,173240013,1,20191125,,,,173240013,1,HIV infection
17364204,173642046,6,F,,20200520,20200204,20200529,EXP,,FR-AUROBINDO-AUR-APL-2020-004851,AUROBINDO,,,,N,M,Y,3.23,KG,20200529,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,173642046,OT,,,173642046,3,20070403,20070521,,,173642046,1,Product used for unknown indication
17406334,174063342,2,F,,20200615,20200212,20200619,EXP,,CA-ROCHE-2545803,ROCHE,,54,YR,,M,Y,,,20200619,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,174063342,OT,,,,,,,,,174063342,1,Bipolar disorder
17412233,174122334,4,F,2015,20200506,20200213,20200602,EXP,,US-GILEAD-2020-0450638,GILEAD,,57,YR,A,M,Y,81.6,KG,20200602,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Suicidal ideation,174122334,OT,,,174122334,1,201505,201508,,,174122334,1,HIV infection
17423538,174235382,2,F,,20200610,20200217,20200622,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-009805,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200622,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,174235382,OT,,,,,,,,,174235382,1,HIV infection
17424136,174241363,3,F,20100506,20200506,20200217,20200526,EXP,,US-GILEAD-2020-0450654,GILEAD,,48,YR,A,M,Y,,,20200526,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Hip arthroplasty;Pain;Renal failure,174241363,HO,,,174241363,1,20070109,200704,,,174241363,1,HIV infection
17489680,174896802,2,F,2017,20200527,20200303,20200602,EXP,,PT-GILEAD-2020-0452706,GILEAD,,45,YR,A,M,Y,,,20200602,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute myocardial infarction;Blood creatinine abnormal;Cardiac failure acute;Cardiorenal syndrome;Dyslipidaemia;Headache;Hepatic function abnormal;Insomnia;Renal disorder;Renal impairment,174896802,OT,,,174896802,1,2011,2017,,,174896802,1,HIV infection
17548280,175482803,3,F,1996,20200401,20200317,20200408,EXP,,ES-AUROBINDO-AUR-APL-2020-012619,AUROBINDO,,38,YR,,M,Y,,,20200408,,HP,CL,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,175482803,OT,,,175482803,1,2001,2001,,,175482803,1,HIV infection
17549433,175494333,3,F,,20200312,20200317,20200526,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK046275,VIIV,,,,,,Y,,,20200526,,CN,US,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175494333,CA,,,,,,,,,175494333,1,HIV infection
17549495,175494953,3,F,,20200312,20200317,20200526,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK046275,GLAXOSMITHKLINE,,,,,,Y,,,20200526,,CN,US,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175494953,CA,,,,,,,,,175494953,1,HIV infection
17583391,175833912,2,F,,20200604,20200326,20200606,EXP,,PE-AUROBINDO-AUR-APL-2020-015876,AUROBINDO,,32,YR,,F,Y,,,20200606,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis;Histoplasmosis,175833912,HO,,,,,,,,,175833912,1,HIV infection
17584138,175841382,2,F,,20200604,20200326,20200606,EXP,,PE-AUROBINDO-AUR-APL-2020-015875,AUROBINDO,,33,YR,,F,Y,,,20200606,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis;Histoplasmosis disseminated,175841382,HO,,,,,,,,,175841382,1,HIV infection
17585048,175850482,2,F,20200316,20200401,20200326,20200410,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-026067,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200410,,CN,GB,GB,EFAVIRENZ.,Death,175850482,OT,,,,,,,,,175850482,1,Product used for unknown indication
17587129,175871292,2,F,2017,20200609,20200326,20200611,EXP,,PT-MYLANLABS-2020M1031812,MYLAN,,45,YR,,M,Y,,,20200611,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute myocardial infarction;Blood creatinine abnormal;Cardiac failure acute;Cardiorenal syndrome;Dyslipidaemia;Headache;Hepatic function abnormal;Insomnia;Renal disorder;Renal impairment,175871292,HO,,,175871292,1,2011,2017,,,175871292,1,HIV infection
17591915,175919152,2,F,20161221,20200506,20200327,20200527,EXP,,US-GILEAD-2020-0456524,GILEAD,,61,YR,A,M,Y,60.7,KG,20200527,,CN,US,US,SUSTIVA,Bone density decreased;Economic problem;Osteoporosis,175919152,OT,,,175919152,1,20020808,20050321,,,175919152,1,HIV infection
17599576,175995762,2,F,201202,20200515,20200330,20200528,EXP,,US-DSJP-DSU-2020-110303,DAIICHI,,,,,,Y,,,20200528,,CN,US,US,EFAVIRENZ.,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Dehydration;Diarrhoea;Emotional distress;Fanconi syndrome acquired;Nausea;Pain;Pancreatitis;Renal failure;Vomiting,175995762,OT,,,175995762,2,20111010,20120309,,,175995762,1,Product used for unknown indication
17613857,176138571,1,I,,20200320,20200402,20200402,EXP,,CA-ROCHE-2572609,ROCHE,,54,YR,,M,Y,,,20200402,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,176138571,OT,,,,,,,,,176138571,1,Bipolar disorder
17614197,176141975,5,F,2009,20200416,20200402,20200420,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-027483,BRISTOL MYERS SQUIBB,"PANOU E, WATCHORN R, BAKKOUR W, RATYNSKA M, BUNKER CB. MULTIPLE ERUPTIVE DERMATOFIBROMAS IN HIV: AN IMMUNE RECONSTITUTION ASSOCIATED DISEASE. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY(JEADV). 2020;34(2):E100-E101",35,YR,,M,Y,,,20200420,,HP,GB,GB,EFAVIRENZ.,Fibrous histiocytoma;Immune reconstitution inflammatory syndrome,176141975,OT,,,176141975,1,2009,,,,176141975,1,HIV infection
17618617,176186171,1,I,,20200326,20200402,20200402,EXP,,IN-MYLANLABS-2020M1034516,MYLAN,,58,YR,,F,Y,,,20200402,,HP,IN,IN,EFAVIRENZ.,Hyperchloraemia;Hypokalaemia;Metabolic acidosis;Renal tubular acidosis,176186171,HO,,,,,,,,,176186171,1,HIV infection
17619244,176192442,2,F,20120216,20200515,20200402,20200528,EXP,,US-DSJP-DSU-2020-110709,DAIICHI,,,,,,Y,,,20200528,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Dehydration;Diarrhoea;Emotional distress;Fanconi syndrome;Nausea;Pain;Pancreatitis;Renal failure;Vomiting,176192442,OT,,,176192442,4,20111010,20120309,,,176192442,1,Product used for unknown indication
17620198,176201981,1,I,20191115,20200330,20200403,20200403,EXP,,CN-GLAXOSMITHKLINE-CN2020APC055904,GLAXOSMITHKLINE,,28,YR,,M,Y,66,KG,20200403,,HP,CN,CN,EFAVIRENZ TABLETS,Drug eruption;Drug-induced liver injury;Hepatic failure;Liver injury;Pyrexia;Rash,176201981,OT,,,176201981,1,20191031,20191225,,,176201981,1,Acquired immunodeficiency syndrome
17620215,176202151,1,I,20191115,20200330,20200403,20200403,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020APC055904,VIIV,,28,YR,,M,Y,66,KG,20200403,,HP,CN,CN,EFAVIRENZ TABLETS,Drug eruption;Drug-induced liver injury;Hepatic failure;Liver injury;Pyrexia;Rash,176202151,HO,,,176202151,1,20191031,20191225,,,176202151,1,Acquired immunodeficiency syndrome
17621214,176212141,1,I,20130601,20200401,20200403,20200403,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-028000,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,89.21,KG,20200403,,LW,US,US,SUSTIVA,Chronic kidney disease;Hepatic enzyme increased;Hydronephrosis;Nephritis allergic;Renal failure;Urinary tract obstruction;Urosepsis,176212141,HO,,,176212141,1,20110729,201709,,,176212141,1,HIV infection
17621265,176212651,1,I,,20200326,20200403,20200403,EXP,,US-MYLANLABS-2020M1034601,MYLAN,,7,DEC,,M,Y,,,20200403,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury,176212651,OT,,,,,,,,,176212651,1,Hepato-lenticular degeneration
17629307,176293071,1,I,2009,20200330,20200406,20200406,EXP,,GB-TEVA-2020-GB-1218717,TEVA,PANOU E. MULTIPLE ERUPTIVE DERMATOFIBROMAS IN HIV: AN IMMUNE RECONSTITUTION ASSOCIATED DISEASE?. J-EUR-ACAD-DERMATOL-VENEREOL.,35,YR,,M,Y,,,20200406,,HP,GB,GB,EFAVIRENZ.,Fibrous histiocytoma;Immune reconstitution inflammatory syndrome,176293071,OT,,,176293071,1,2009,,,,176293071,1,HIV infection
17643674,176436742,2,F,2009,20200407,20200408,20200420,EXP,,GB-AUROBINDO-AUR-APL-2020-016531,AUROBINDO,,35,YR,,M,Y,,,20200420,,HP,GB,GB,EFAVIRENZ.,Drug resistance;Fibrous histiocytoma;Immune reconstitution inflammatory syndrome,176436742,OT,,,176436742,1,2009,,,,176436742,1,HIV infection
17643696,176436961,1,I,20200316,20200401,20200408,20200408,EXP,,GB-AUROBINDO-AUR-APL-2020-017206,AUROBINDO,,,,,M,Y,,,20200408,,CN,GB,GB,EFAVIRENZ FILM-COATED TABLET 600MG,Death,176436961,DE,,,,,,,,,176436961,1,Product used for unknown indication
17646051,176460511,1,I,,20200404,20200408,20200408,EXP,,GB-MYLANLABS-2020M1035489,MYLAN,,,,,F,Y,,,20200408,,CN,GB,GB,EFAVIRENZ MYLAN 600 MG FILM-COATED TABLETS,Coronavirus infection;Cough,176460511,OT,,,,,,,,,176460511,1,Product used for unknown indication
17646796,176467961,1,I,,20200406,20200408,20200408,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029010,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20200408,,HP,CA,CA,SUSTIVA,Anxiety,176467961,HO,,,,,,,,,176467961,1,HIV infection
17650432,176504321,1,I,20091201,20200408,20200409,20200409,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029565,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20200409,,MD,DE,DE,SUSTIVA,Superficial spreading melanoma stage unspecified,176504321,LT,,,,,,,,,176504321,1,HIV infection
17651643,176516431,1,I,,20200408,20200409,20200409,EXP,,GB-MYLANLABS-2020M1036003,MYLAN,,,,,M,Y,,,20200409,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection;Cough;Myalgia;Pneumonia,176516431,OT,,,,,,,,,176516431,1,Product used for unknown indication
17653758,176537581,1,I,,20200406,20200410,20200410,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029047,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200410,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176537581,OT,,,,,,,,,176537581,1,HIV infection
17653762,176537621,1,I,,20200406,20200410,20200410,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029009,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200410,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176537621,OT,,,,,,,,,176537621,1,HIV infection
17658837,176588371,1,I,,20200406,20200413,20200413,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029074,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200413,,HP,CA,CA,SUSTIVA,Depression;Labelled drug-drug interaction medication error,176588371,HO,,,,,,,,,176588371,1,Product used for unknown indication
17661614,176616141,1,I,,20200406,20200413,20200413,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029069,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20200413,,HP,CA,CA,SUSTIVA,Anxiety,176616141,HO,,,,,,,,,176616141,1,HIV infection
17664037,176640371,1,I,,20200408,20200414,20200414,EXP,,CA-009507513-2004CAN002935,MERCK,,,,,,Y,,,20200414,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,176640371,OT,,,,,,,,,176640371,1,HIV infection
17665268,176652681,1,I,,20200406,20200414,20200414,EXP,,GB-MYLANLABS-2020M1037153,MYLAN,,,,A,F,Y,,,20200414,,HP,GB,GB,EFAVIRENZ.,Hypertension;Maternal exposure during breast feeding;Maternal exposure during pregnancy;Pre-eclampsia,176652681,OT,,,,,,,,,176652681,1,HIV infection
17666423,176664231,1,I,,20200331,20200414,20200414,EXP,,IN-GUARDIAN DRUG COMPANY-2082842,GUARDIAN PHARMACEUTICALS,"IBUPROFEN-INDUCED INTRA-ORAL FIXED DRUG ERUPTION.?SAI PAWAN AR, SWAMY VHT, MOTHI SN, YASHASWINI.Y.?JOURNAL OF PHARMACY PRACTICE AND RESEARCH, 2019, 1-4.",35,YR,,F,Y,,,20200414,,PH,IN,IN,EFAVIRENZ.,Dysphagia;Fixed eruption,176664231,HO,,,,,,,,,176664231,1,Postoperative analgesia
17668123,176681231,1,I,,20200406,20200415,20200415,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-028941,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200415,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176681231,OT,,,,,,,,,176681231,1,Product used for unknown indication
17668145,176681451,1,I,,20200406,20200415,20200415,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029032,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200415,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176681451,OT,,,,,,,,,176681451,1,HIV infection
17668430,176684301,1,I,,20200406,20200415,20200415,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029250,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200415,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176684301,OT,,,,,,,,,176684301,1,Product used for unknown indication
17672027,176720271,1,I,2014,20200407,20200415,20200415,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2020GSK060636,VIIV,"LAITON-DONATO K, AVILA-ROBAYO P, PAEZ-MARTINEZ A, BENJUMEA-NIETO P, USME-CIRO JA, PINZON-NARINO N ET AL.. PROGRESSIVE VACCINIA ACQUIRED THROUGH ZOONOTIC TRANSMISSION IN A PATIENT WITH HIV/AIDS, COLOMBIA. EMERGING INFECTIOUS DISEASES. 2020;26 (3):601-605 DOI.ORG/10.3201/EID260",30,YR,,M,Y,,,20200415,,MD,CO,CO,EFAVIRENZ.,Anaemia;Condition aggravated;General physical health deterioration;Hypoacusis;Leukopenia;Pathogen resistance;Progressive vaccinia;Pyrexia;Skin lesion;Skin ulcer;Tachycardia;Treatment noncompliance;Virologic failure;Visual impairment,176720271,OT,,,176720271,1,,20150330,,,176720271,1,HIV infection
17673683,176736831,1,I,,20080116,20200415,20200415,EXP,,IT-009507513-0801ITA00021,MERCK,,50,YR,,M,Y,,,20200415,,CN,IT,IT,EFAVIRENZ.,Atrial hypertrophy;Blood cholesterol increased;Blood triglycerides increased;Body fat disorder;Hypertension;Hypertensive crisis;Left ventricular hypertrophy;Lipoatrophy;Posterior reversible encephalopathy syndrome,176736831,HO,,,,,,,,,176736831,1,HIV infection
17674968,176749682,2,F,,20200420,20200416,20200423,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029068,BRISTOL MYERS SQUIBB,"RIDOLFO AL, RESTA F, MILAZZO L, CARAMMA I, MATACENA G, ANTINORI S, ET AL.. REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME IN 2 HIV INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY. CLINICAL INFECTIOUS DISEASES. 2008;46:E19-22",50,YR,,M,Y,,,20200423,,HP,IT,IT,EFAVIRENZ.,Posterior reversible encephalopathy syndrome,176749682,HO,,,,,,,,,176749682,1,Antiretroviral therapy
17676153,176761531,1,I,,20200409,20200416,20200416,EXP,,CA-ROCHE-2583102,ROCHE,,54,YR,,M,Y,,,20200416,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176761531,OT,,,,,,,,,176761531,1,Bipolar disorder
17677796,176777962,2,F,,20200615,20200416,20200616,EXP,,CA-ROCHE-2582751,ROCHE,,54,YR,,M,Y,,,20200616,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176777962,DE,,,,,,,,,176777962,1,Bipolar disorder
17677809,176778091,1,I,,20200410,20200416,20200416,EXP,,CA-ROCHE-2583351,ROCHE,,54,YR,,M,Y,,,20200417,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176778091,OT,,,,,,,,,176778091,1,HIV infection
17677966,176779661,1,I,,20200409,20200417,20200417,EXP,,CA-ROCHE-2582903,ROCHE,,,,,M,Y,,,20200417,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,176779661,OT,,,,,,,,,176779661,1,Product used for unknown indication
17678150,176781501,1,I,,20180507,20200417,20200417,EXP,,CA-ROCHE-2120444,ROCHE,,44,YR,,M,Y,,,20200417,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,176781501,HO,,,,,,,,,176781501,1,Product used for unknown indication
17679010,176790102,2,F,20091201,20200412,20200417,20200421,EXP,DE-DCGMA-20184716,DE-TEVA-2020-DE-1224251,TEVA,,44,YR,,M,Y,,,20200421,,MD,DE,DE,EFAVIRENZ.,Superficial spreading melanoma stage unspecified,176790102,LT,,,,,,,,,176790102,1,HIV infection
17680349,176803491,1,I,,20200410,20200417,20200417,EXP,,CA-ROCHE-2583150,ROCHE,,,,,M,Y,,,20200417,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction,176803491,OT,,,,,,,,,176803491,1,Product used for unknown indication
17680666,176806661,1,I,,20200413,20200417,20200417,EXP,,GF-GLAXOSMITHKLINE-GF2020GSK064965,GLAXOSMITHKLINE,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200417,,HP,GF,GF,EFAVIRENZ.,Abdominal pain;Diarrhoea;Dyspnoea;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia;Virologic failure,176806661,OT,,,,,,,,,176806661,1,HIV infection
17680667,176806671,1,I,,20200413,20200417,20200417,EXP,,GF-VIIV HEALTHCARE LIMITED-GF2020GSK064965,VIIV,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200417,,HP,GF,GF,EFAVIRENZ.,Abdominal pain;Diarrhoea;Dyspnoea;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia;Virologic failure,176806671,OT,,,,,,,,,176806671,1,HIV infection
17683018,176830181,1,I,,20200410,20200420,20200420,EXP,,CA-ROCHE-2583373,ROCHE,,54,YR,,M,Y,,,20200420,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,176830181,OT,,,,,,,,,176830181,1,Bipolar disorder
17684290,176842901,1,I,,20200413,20200420,20200420,EXP,,GF-GLAXOSMITHKLINE-GF2020GSK065897,GLAXOSMITHKLINE,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200420,,HP,GF,GF,EFAVIRENZ.,Anaemia;Arthralgia;Condition aggravated;Diarrhoea;Encephalitis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia,176842901,OT,,,,,,,,,176842901,1,HIV infection
17684293,176842931,1,I,,20200413,20200420,20200420,EXP,,GF-VIIV HEALTHCARE LIMITED-GF2020GSK065897,VIIV,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200420,,HP,GF,GF,EFAVIRENZ.,Anaemia;Arthralgia;Condition aggravated;Diarrhoea;Encephalitis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia,176842931,OT,,,,,,,,,176842931,1,HIV infection
17684348,176843481,1,I,,20200413,20200420,20200420,EXP,,GF-VIIV HEALTHCARE LIMITED-GF2020GSK065908,VIIV,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200420,,HP,GF,GF,EFAVIRENZ.,Acute kidney injury;Anaemia;Diarrhoea;Hepatomegaly;Histoplasmosis;Immune reconstitution inflammatory syndrome;Pyrexia;Weight decreased,176843481,HO,,,,,,,,,176843481,1,HIV infection
17684351,176843511,1,I,,20200413,20200420,20200420,EXP,,GF-GLAXOSMITHKLINE-GF2020GSK065908,GLAXOSMITHKLINE,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLINICAL INFECTIOUS DISEASES. 2020;70 (4):643-652, DOI.10.1093/CID/CIZ24",,,A,,Y,,,20200420,,HP,GF,GF,EFAVIRENZ.,Acute kidney injury;Anaemia;Diarrhoea;Hepatomegaly;Histoplasmosis;Immune reconstitution inflammatory syndrome;Pyrexia;Weight decreased,176843511,OT,,,,,,,,,176843511,1,HIV infection
17684543,176845431,1,I,,20200413,20200420,20200420,EXP,,CA-ROCHE-2583703,ROCHE,,52,YR,,M,Y,,,20200420,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,176845431,OT,,,,,,,,,176845431,1,HIV infection
17685877,176858771,1,I,20171006,20200214,20200420,20200420,EXP,,NVSC2020GB043058,NOVARTIS,,43,YR,,F,Y,,,20200420,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,176858771,OT,,,176858771,1,20171006,20180205,,,176858771,1,HIV infection
17685920,176859201,1,I,,20200407,20200420,20200420,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK067790,VIIV,,36,YR,,M,Y,,,20200420,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176859201,OT,,,,,,,,,176859201,1,HIV infection
17685921,176859211,1,I,,20200407,20200420,20200420,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK067790,GLAXOSMITHKLINE,,36,YR,,M,Y,,,20200420,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176859211,OT,,,,,,,,,176859211,1,HIV infection
17686173,176861731,1,I,,20200407,20200420,20200420,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK067727,VIIV,,28,YR,,M,Y,,,20200420,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176861731,OT,,,,,,,,,176861731,1,HIV infection
17686174,176861741,1,I,,20200407,20200420,20200420,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK067727,GLAXOSMITHKLINE,,28,YR,,M,Y,,,20200420,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176861741,OT,,,,,,,,,176861741,1,HIV infection
17686711,176867111,1,I,,20200410,20200421,20200421,EXP,,GB-AUROBINDO-AUR-APL-2020-019780,AUROBINDO,,,,,M,Y,,,20200421,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection;Cough;Myalgia;Pneumonia,176867111,OT,,,,,,,,,176867111,1,Product used for unknown indication
17686800,176868001,1,I,,20200410,20200421,20200421,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-030591,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200421,,CN,GB,GB,SUSTIVA,Coronavirus infection;Cough;Myalgia;Pneumonia,176868001,OT,,,,,,,,,176868001,1,Product used for unknown indication
17687492,176874922,2,F,,20200407,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK067791,GLAXOSMITHKLINE,,32,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176874922,OT,,,,,,,,,176874922,1,HIV infection
17687523,176875232,2,F,,20200407,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK067791,VIIV,,32,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176875232,OT,,,,,,,,,176875232,1,HIV infection
17688040,176880401,1,I,,20200407,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK067793,VIIV,,36,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176880401,OT,,,,,,,,,176880401,1,HIV infection
17688148,176881481,1,I,,20200407,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK068224,VIIV,,42,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176881481,OT,,,,,,,,,176881481,1,HIV infection
17688151,176881511,1,I,,20200407,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK068224,GLAXOSMITHKLINE,,42,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176881511,OT,,,,,,,,,176881511,1,HIV infection
17688433,176884331,1,I,,20200407,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK068225,GLAXOSMITHKLINE,,41,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ + EMTRICITABINE + TENOFOVIR;EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176884331,OT,,,,,,,,,176884331,1,HIV infection
17688440,176884401,1,I,,20200407,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK068225,VIIV,,41,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ + EMTRICITABINE + TENOFOVIR;EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176884401,OT,,,,,,,,,176884401,1,HIV infection
17689023,176890231,1,I,,20200414,20200421,20200421,EXP,,FR-ABBVIE-20K-056-3367592-00,ABBVIE,,,,,M,Y,,,20200421,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Hydrocele,176890231,OT,,,,,,,,,176890231,1,Maternal exposure timing unspecified
17689185,176891851,1,I,,20200407,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK068226,VIIV,,29,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Pathogen resistance;Viral mutation identified;Virologic failure,176891851,OT,,,,,,,,,176891851,1,HIV infection
17689186,176891861,1,I,,20200407,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK068226,GLAXOSMITHKLINE,,29,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Pathogen resistance;Viral mutation identified;Virologic failure,176891861,OT,,,,,,,,,176891861,1,HIV infection
17689207,176892071,1,I,,20200407,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK068410,GLAXOSMITHKLINE,,50,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176892071,OT,,,,,,,,,176892071,1,HIV infection
17689225,176892251,1,I,,20200407,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK068410,VIIV,,50,YR,,M,Y,,,20200421,,HP,TW,TW,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176892251,OT,,,,,,,,,176892251,1,HIV infection
17692547,176925471,1,I,,20200415,20200422,20200422,EXP,,US-MYLANLABS-2020M1040591,MYLAN,"DOOLEY KE, KAPLAN R, MWELASE N, GRINSZTEJN B, TICONA E, LACERDA M, ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY FOR PATIENTS COINFECTED WITH TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS: A MULTICENTER, NONCOMPARATIVE, OPEN-LABEL, RANDOMIZED TRIAL. CLIN-INFECT-DIS 2020;70(4):549-556.",,,A,F,Y,,,20200422,,HP,US,US,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,176925471,OT,,,,,,,,,176925471,1,HIV infection
17692553,176925531,1,I,,20200415,20200422,20200422,EXP,,US-MYLANLABS-2020M1040596,MYLAN,"DOOLEY KE, KAPLAN R, MWELASE N, GRINSZTEJN B, TICONA E, LACERDA M, ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY FOR PATIENTS COINFECTED WITH TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS: A MULTICENTER, NONCOMPARATIVE, OPEN-LABEL, RANDOMIZED TRIAL. CLIN-INFECT-DIS 2020;70(4):549-556.",,,A,,Y,,,20200422,,HP,US,US,EFAVIRENZ.,Acute kidney injury;Immune reconstitution inflammatory syndrome,176925531,OT,,,,,,,,,176925531,1,HIV infection
17696743,176967431,1,I,,20200411,20200423,20200423,EXP,,IN-HETERO-HET2020IN00414,HETERO,"SEN P, SUDHARSHAN S, BANERJEE A, DHAMI A.. CLINICAL AND ELECTROPHYSIOLOGICAL CHARACTERISTICS OF EFAVIRENZ-INDUCED MACULAR TOXICITY. GMS OPHTHALMOL CASES. 2020;10 (8):1-5",54,YR,,F,Y,,,20200423,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity,176967431,OT,,,,,,,,,176967431,1,HIV infection
17700830,177008301,1,I,,20200422,20200423,20200423,EXP,,GB-MYLANLABS-2020M1041119,MYLAN,,,,,M,Y,,,20200423,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,177008301,HO,,,,,,,,,177008301,1,Product used for unknown indication
17704872,177048721,1,I,,20200415,20200424,20200424,EXP,,US-MYLANLABS-2020M1040599,MYLAN,"DOOLEY KE, KAPLAN R, MWELASE N, GRINSZTEJN B, TICONA E, LACERDA M, ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY FOR PATIENTS COINFECTED WITH TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS: A MULTICENTER, NONCOMPARATIVE, OPEN-LABEL, RANDOMIZED TRIAL. CLIN-INFECT-DIS 2020;70(4):549-556.",,,A,,Y,,,20200424,,HP,US,US,EFAVIRENZ.,Drug resistance;Virologic failure,177048721,OT,,,,,,,,,177048721,1,HIV infection
17704879,177048791,1,I,,20200415,20200424,20200424,EXP,,US-MYLANLABS-2020M1040598,MYLAN,"DOOLEY KE, KAPLAN R, MWELASE N, GRINSZTEJN B, TICONA E, LACERDA M, ET AL. DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY FOR PATIENTS COINFECTED WITH TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS: A MULTICENTER, NONCOMPARATIVE, OPEN-LABEL, RANDOMIZED TRIAL. CLIN-INFECT-DIS 2020;70(4):549-556.",,,A,,Y,,,20200424,,HP,US,US,EFAVIRENZ.,Treatment failure,177048791,OT,,,,,,,,,177048791,1,Tuberculosis
17707929,177079291,1,I,,20200420,20200425,20200425,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020607",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200425,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,177079291,OT,,,,,,,,,177079291,1,HIV infection
17709802,177098021,1,I,,20200420,20200427,20200427,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020596",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200427,,HP,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177098021,OT,,,,,,,,,177098021,1,HIV infection
17709804,177098041,1,I,,20200415,20200427,20200427,EXP,,GB-AUROBINDO-AUR-APL-2020-020175,AUROBINDO,,,,A,F,Y,,,20200427,,HP,GB,GB,EFAVIRENZ.,Hypertension;Maternal exposure during breast feeding;Maternal exposure during pregnancy;Pre-eclampsia,177098041,OT,,,,,,,,,177098041,1,HIV infection
17709831,177098311,1,I,,20200420,20200427,20200427,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020619",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200427,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,177098311,CA,,,,,,,,,177098311,1,HIV infection
17710102,177101021,1,I,,20200420,20200427,20200427,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020641",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200427,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,177101021,OT,,,,,,,,,177101021,1,HIV infection
17715956,177159561,1,I,,20200418,20200428,20200428,EXP,,IT-AUROBINDO-AUR-APL-2020-020537,AUROBINDO,,50,YR,,M,Y,,,20200428,,MD,IT,IT,EFAVIRENZ.,Atrial hypertrophy;Blood cholesterol increased;Blood triglycerides increased;Body fat disorder;Hypertension;Hypertensive crisis;Left ventricular hypertrophy;Lipoatrophy;Posterior reversible encephalopathy syndrome,177159561,HO,,,,,,,,,177159561,1,HIV infection
17716006,177160061,1,I,,20200421,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020921",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200428,,HP,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177160061,OT,,,,,,,,,177160061,1,HIV infection
17716091,177160911,1,I,,20200421,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020886",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200428,,MD,CA,CA,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL MALEATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177160911,OT,,,,,,,,,177160911,1,HIV infection
17716104,177161041,1,I,,20200421,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020959",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200428,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,177161041,OT,,,,,,,,,177161041,1,HIV infection
17716181,177161811,1,I,,20200421,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-021213",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200428,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,177161811,OT,,,,,,,,,177161811,1,HIV infection
17716385,177163851,1,I,,20200421,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020997",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200428,,HP,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177163851,OT,,,,,,,,,177163851,1,HIV infection
17716532,177165321,1,I,,20200421,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020924",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200428,,HP,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177165321,OT,,,,,,,,,177165321,1,Product used for unknown indication
17716551,177165511,1,I,,20200421,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020873",BOEHRINGER INGELHEIM,,,,,,Y,,,20200428,,HP,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177165511,OT,,,,,,,,,177165511,1,HIV infection
17717701,177177011,1,I,,20200420,20200428,20200428,EXP,,FR-MYLANLABS-2020M1042155,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200428,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177177011,HO,,,,,,,,,177177011,1,HIV infection
17717704,177177041,1,I,,20200420,20200428,20200428,EXP,,FR-MYLANLABS-2020M1042160,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200428,,HP,FR,FR,EFAVIRENZ.,Condition aggravated;Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177177041,HO,,,,,,,,,177177041,1,HIV infection
17717710,177177101,1,I,,20200420,20200428,20200428,EXP,,FR-MYLANLABS-2020M1042132,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200428,,HP,FR,FR,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177177101,HO,,,,,,,,,177177101,1,HIV infection
17722739,177227391,1,I,,20200420,20200429,20200429,EXP,,FR-MYLANLABS-2020M1042126,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200429,,HP,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177227391,HO,,,,,,,,,177227391,1,HIV infection
17722779,177227791,1,I,,20200420,20200429,20200429,EXP,,FR-MYLANLABS-2020M1042129,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200429,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177227791,HO,,,,,,,,,177227791,1,HIV infection
17723099,177230991,1,I,,20200420,20200429,20200429,EXP,,FR-MYLANLABS-2020M1042142,MYLAN,"MELZANI A, DE REYNAL DE SAINT MICHEL R, NTAB B, DJOSSOU F, EPELBOIN L, NACHER M, ET AL. INCIDENCE AND TRENDS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH HISTOPLASMA CAPSULATUM AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS: A 20-YEAR CASE SERIES AND LITERATURE REVIEW. CLIN-INFECT-DIS 2020;70(4):643-652.",,,,,Y,,,20200429,,HP,FR,FR,EFAVIRENZ.,Acute kidney injury;Condition aggravated;Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177230991,HO,,,,,,,,,177230991,1,HIV infection
17723323,177233231,1,I,,20200415,20200429,20200429,EXP,,CH-GLAXOSMITHKLINE-MM2020GSK071237,GLAXOSMITHKLINE,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177233231,OT,,,,,,,,,177233231,1,HIV infection
17723325,177233251,1,I,,20200415,20200429,20200429,EXP,,CH-VIIV HEALTHCARE LIMITED-MM2020GSK071237,VIIV,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177233251,OT,,,,,,,,,177233251,1,HIV infection
17723508,177235081,1,I,,20200415,20200429,20200429,EXP,,CH-GLAXOSMITHKLINE-MM2020GSK071240,GLAXOSMITHKLINE,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177235081,OT,,,,,,,,,177235081,1,HIV infection
17723511,177235111,1,I,,20200415,20200429,20200429,EXP,,CH-VIIV HEALTHCARE LIMITED-MM2020GSK071240,VIIV,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177235111,OT,,,,,,,,,177235111,1,HIV infection
17724867,177248671,1,I,,20200425,20200429,20200429,EXP,,CA-BAUSCH-BL-2020-012621,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200429,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177248671,OT,,,,,,,,,177248671,1,Bipolar disorder
17724870,177248701,1,I,,20200425,20200429,20200429,EXP,,CA-BAUSCH-BL-2020-012574,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200429,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177248701,OT,,,,,,,,,177248701,1,Bipolar disorder
17725483,177254831,1,I,,20200415,20200429,20200429,EXP,,CH-GLAXOSMITHKLINE-MM2020GSK071242,GLAXOSMITHKLINE,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177254831,OT,,,,,,,,,177254831,1,HIV infection
17725484,177254841,1,I,,20200415,20200429,20200429,EXP,,CH-VIIV HEALTHCARE LIMITED-MM2020GSK071242,VIIV,"MURRAY J, WHITEHOUSE K, OUSLEY J, BERMUDEZ E, SOE TT, HILBIG A ET AL.. HIGH LEVELS OF VIRAL REPRESSION, MALNUTRITION AND SECOND-LINE ART USE IN ADOLESCENTS LIVING WITH HIV: A MIXED METHODS STUDY FROM MYANMAR. BMC INFECTIOUS DISEASES. 2020;20(1):DOI:10.1186/S12879-020-04968-X",,,,,Y,,,20200429,,HP,CH,MM,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177254841,OT,,,,,,,,,177254841,1,HIV infection
17725808,177258081,1,I,,20200425,20200429,20200429,EXP,,CA-BAUSCH-BL-2020-012602,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200429,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,177258081,OT,,,,,,,,,177258081,1,Bipolar disorder
17725822,177258221,1,I,,20200425,20200429,20200429,EXP,,CA-BAUSCH-BL-2020-012619,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200429,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177258221,OT,,,,,,,,,177258221,1,Product used for unknown indication
17725848,177258481,1,I,,20200425,20200429,20200429,EXP,,CA-BAUSCH-BL-2020-012622,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200429,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177258481,OT,,,,,,,,,177258481,1,Bipolar disorder
17727899,177278991,1,I,,20200425,20200430,20200430,EXP,,CA-BAUSCH-BL-2020-012623,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200430,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177278991,OT,,,,,,,,,177278991,1,Bipolar disorder
17727902,177279021,1,I,,20200425,20200430,20200430,EXP,,CA-BAUSCH-BL-2020-012629,BAUSCH AND LOMB,,,,,M,Y,,,20200430,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177279021,HO,,,,,,,,,177279021,1,Product used for unknown indication
17727904,177279041,1,I,,20200425,20200430,20200430,EXP,,CA-BAUSCH-BL-2020-012627,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200430,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177279041,OT,,,,,,,,,177279041,1,Product used for unknown indication
17729780,177297801,1,I,,20200421,20200430,20200430,EXP,,CH-JNJFOC-20200430981,JOHNSON AND JOHNSON,"KOVARI H, CALMY A, DOCO-LECOMPTE T, NKOULOU R, MARZEL A, WEBER R, PHILIPP A. K, RONNY R. B, LEDERGERBER B, PHILIP E. T. ANTIRETROVIRAL DRUGS ASSOCIATED WITH SUBCLINICAL CORONARY ARTERY DISEASE IN THE SWISS HUMAN IMMUNODEFICIENCY VIRUS COHORT STUDY. CLIN INFECT DIS. 70(5):884-889.",,,,,Y,,,20200430,,HP,CH,CH,EFAVIRENZ.,Coronary artery disease,177297801,OT,,,,,,,,,177297801,1,HIV infection
17730009,177300091,1,I,,20200427,20200430,20200430,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-034390,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200430,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,177300091,HO,,,,,,,,,177300091,1,Product used for unknown indication
17730672,177306721,1,I,20200326,20200427,20200430,20200430,EXP,,GB-MYLANLABS-2020M1042440,MYLAN,,,,A,F,Y,,,20200430,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,177306721,OT,,,,,,,,,177306721,1,Product used for unknown indication
17732671,177326711,1,I,,20200425,20200501,20200501,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK074404,VIIV,,54,YR,,M,Y,,,20200501,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,177326711,OT,,,,,,,,,177326711,1,Bipolar disorder
17732677,177326771,1,I,,20200425,20200501,20200501,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK074404,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20200501,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,177326771,OT,,,,,,,,,177326771,1,Bipolar disorder
17734920,177349201,1,I,202004,20200427,20200501,20200501,EXP,,GB-MYLANLABS-2020M1042783,MYLAN,,,,,F,Y,,,20200501,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,177349201,OT,,,,,,,,,177349201,1,Product used for unknown indication
17741422,177414221,1,I,,20200428,20200504,20200504,EXP,,IT-MYLANLABS-2020M1042727,MYLAN,,50,YR,,M,Y,,,20200504,,MD,IT,IT,EFAVIRENZ.,Agitation;Asthenia;Blood cholesterol increased;Blood triglycerides increased;Body fat disorder;Coma;Confusional state;Extensor plantar response;Facial paralysis;Hydrocephalus;Hyperreflexia;Hypertension;Hypertensive crisis;Left atrial hypertrophy;Left ventricular hypertrophy;Lipodystrophy acquired;Loss of consciousness;Papilloedema;Posterior reversible encephalopathy syndrome;Pyrexia;Tachycardia;Vasogenic cerebral oedema;Waist circumference increased,177414221,HO,,,,,,,,,177414221,1,Antiretroviral therapy
17743771,177437711,1,I,,20200425,20200505,20200505,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK075602,VIIV,,54,YR,,M,Y,,,20200505,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,177437711,OT,,,,,,,,,177437711,1,Bipolar disorder
17743782,177437821,1,I,,20200425,20200505,20200505,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK075602,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20200505,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,177437821,OT,,,,,,,,,177437821,1,Bipolar disorder
17753739,177537391,1,I,,20200427,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-021832,AUROBINDO,,,,,,Y,,,20200507,,HP,FR,FR,EFAVIRENZ.,Abdominal pain;Cough;Diarrhoea;Dyspnoea;Haemophagocytic lymphohistiocytosis;Hepatomegaly;Histoplasmosis;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Pyrexia,177537391,HO,,,,,,,,,177537391,1,HIV infection
17754134,177541341,1,I,,20200429,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-022131,AUROBINDO,,,,,,Y,,,20200507,,HP,FR,FR,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177541341,HO,,,,,,,,,177541341,1,HIV infection
17754160,177541601,1,I,,20200429,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-022134,AUROBINDO,,,,,,Y,,,20200507,,HP,FR,FR,EFAVIRENZ.,Condition aggravated;Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177541601,HO,,,,,,,,,177541601,1,HIV infection
17754175,177541751,1,I,,20200429,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-022136,AUROBINDO,,,,,,Y,,,20200507,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177541751,OT,,,,,,,,,177541751,1,HIV infection
17754258,177542581,1,I,,20200427,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-021830,AUROBINDO,,,,,,Y,,,20200507,,HP,FR,FR,EFAVIRENZ.,Anaemia;Dyspnoea;Hepatocellular injury;Histoplasmosis;Immune reconstitution inflammatory syndrome;Neurological symptom;Pyrexia;Weight decreased,177542581,HO,,,,,,,,,177542581,1,HIV infection
17754789,177547891,1,I,20200326,20200430,20200507,20200507,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-035444,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20200507,,CN,GB,GB,SUSTIVA,Coronavirus infection,177547891,OT,,,,,,,,,177547891,1,Product used for unknown indication
17754797,177547971,1,I,,20200427,20200507,20200507,EXP,,FR-AUROBINDO-AUR-APL-2020-021826,AUROBINDO,,,,,,Y,,,20200507,,HP,FR,FR,EFAVIRENZ.,Anaemia;Arthralgia;Diarrhoea;Encephalitis;Histoplasmosis;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Pyrexia,177547971,HO,,,,,,,,,177547971,1,HIV infection
17758708,177587081,1,I,202004,20200501,20200508,20200508,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-035850,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200508,,CN,GB,GB,EFAVIRENZ.,SARS-CoV-2 test positive,177587081,OT,,,,,,,,,177587081,1,Product used for unknown indication
17758738,177587382,2,F,,20200504,20200507,20200518,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-018592,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200518,,MD,US,BW,EFAVIRENZ.,Arnold-Chiari malformation;Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,177587382,OT,,,,,,,,,177587382,1,Product used for unknown indication
17758801,177588011,1,I,,20200427,20200508,20200508,EXP,,FR-AUROBINDO-AUR-APL-2020-021821,AUROBINDO,,,,,,Y,,,20200508,,HP,FR,FR,EFAVIRENZ.,Anaemia;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Pulmonary interstitial emphysema syndrome;Weight decreased,177588011,OT,,,,,,,,,177588011,1,HIV infection
17759134,177591342,2,F,,20200513,20200508,20200516,EXP,,BW-AUROBINDO-AUR-APL-2020-024122,AUROBINDO,,,,,,Y,,,20200516,,MD,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Stillbirth,177591342,DE,,,,,,,,,177591342,1,Product used for unknown indication
17759277,177592771,1,I,,20191126,20200508,20200508,EXP,,CA-ROCHE-2485311,ROCHE,,45,YR,,M,Y,,,20200508,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,177592771,OT,,,,,,,,,177592771,1,HIV infection
17759420,177594202,2,F,,20200603,20200508,20200612,EXP,,FR-AUROBINDO-AUR-APL-2020-022351,AUROBINDO,,,,,,Y,,,20200612,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction;Unmasking of previously unidentified disease,177594202,OT,,,,,,,,,177594202,1,HIV infection
17759425,177594251,1,I,,20200430,20200508,20200508,EXP,,FR-AUROBINDO-AUR-APL-2020-022349,AUROBINDO,,,,,,Y,,,20200508,,HP,FR,FR,EFAVIRENZ.,Histoplasmosis;Immune reconstitution inflammatory syndrome;Unmasking of previously unidentified disease,177594251,HO,,,,,,,,,177594251,1,HIV infection
17760059,177600592,2,F,20200526,20200601,20200508,20200604,PER,,US-GILEAD-2020-0463938,GILEAD,,19,YR,A,M,Y,,,20200604,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Fatigue;Feeling hot;Off label use;Product use issue,,,,,177600592,1,,20200526,,,177600592,1,Prophylaxis
17764040,177640401,1,I,,20200430,20200511,20200511,EXP,,FR-AUROBINDO-AUR-APL-2020-022263,AUROBINDO,,,,,,Y,,,20200511,,HP,FR,FR,EFAVIRENZ.,Acute kidney injury;Condition aggravated;Histoplasmosis;Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,177640401,HO,,,,,,,,,177640401,1,HIV infection
17764048,177640481,1,I,20200326,20200430,20200511,20200511,EXP,,GB-AUROBINDO-AUR-APL-2020-022020,AUROBINDO,,,,A,F,Y,,,20200511,,CN,GB,GB,EFAVIRENZ.,Coronavirus infection,177640481,OT,,,,,,,,,177640481,1,Product used for unknown indication
17765654,177656541,1,I,,20200503,20200511,20200511,EXP,,CA-TEVA-2020-CA-1233114,TEVA,,54,YR,,M,Y,,,20200511,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,177656541,OT,,,,,,,,,177656541,1,Product used for unknown indication
17765744,177657441,1,I,,20200503,20200511,20200511,EXP,,CA-TEVA-2020-CA-1233158,TEVA,,,,,M,Y,,,20200511,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177657441,HO,,,,,,,,,177657441,1,Product used for unknown indication
17766541,177665412,2,F,,20200616,20200511,20200623,EXP,,CA-TEVA-2020-CA-1233087,TEVA,,54,YR,,M,Y,,,20200623,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177665412,OT,,,,,,,,,177665412,1,Bipolar disorder
17766545,177665451,1,I,,20200503,20200511,20200511,EXP,,CA-TEVA-2020-CA-1233139,TEVA,,54,YR,,M,Y,,,20200511,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177665451,OT,,,,,,,,,177665451,1,Bipolar disorder
17766546,177665461,1,I,,20200503,20200511,20200511,EXP,,CA-TEVA-2020-CA-1233130,TEVA,,54,YR,,M,Y,,,20200511,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,177665461,OT,,,,,,,,,177665461,1,Product used for unknown indication
17768515,177685151,1,I,202004,20200502,20200512,20200512,EXP,,GB-AUROBINDO-AUR-APL-2020-024184,AUROBINDO,,,,,F,Y,,,20200512,,CN,GB,GB,Efavirenz Film-coated Tablet,Coronavirus infection,177685151,OT,,,,,,,,,177685151,1,Product used for unknown indication
17768835,177688351,1,I,20170709,20200502,20200512,20200512,EXP,,ES-AUROBINDO-AUR-APL-2020-023979,AUROBINDO,,71,YR,,M,Y,,,20200512,,MD,ES,ES,EFAVIRENZ.,Upper gastrointestinal haemorrhage,177688351,OT,,,177688351,2,200907,,,,177688351,1,Dyslipidaemia
17778522,177785221,1,I,,20200511,20200513,20200513,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020GSK080340,VIIV,,76,YR,,M,Y,,,20200513,,MD,GB,GB,EFAVIRENZ.,Renal impairment,177785221,OT,,,,,,,,,177785221,1,HIV infection
17779212,177792121,1,I,,20200506,20200513,20200513,EXP,,IT-MYLANLABS-2020M1045913,MYLAN,,50,YR,,M,Y,,,20200513,,CN,IT,IT,EFAVIRENZ.,Atrial hypertrophy;Blood cholesterol increased;Blood triglycerides increased;Body fat disorder;Hypertension;Hypertensive crisis;Left ventricular hypertrophy;Lipoatrophy;Posterior reversible encephalopathy syndrome,177792121,OT,,,,,,,,,177792121,1,HIV infection
17779219,177792191,1,I,,20200506,20200513,20200513,EXP,,GB-MYLANLABS-2020M1046439,MYLAN,,,,,M,Y,,,20200513,,CN,GB,GB,EFAVIRENZ.,COVID-19,177792191,OT,,,,,,,,,177792191,1,Product used for unknown indication
17786904,177869041,1,I,,20200507,20200514,20200514,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081421,VIIV,,,,,,Y,,,20200514,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177869041,OT,,,,,,,,,177869041,1,HIV infection
17786905,177869051,1,I,,20200507,20200514,20200514,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081421,GLAXOSMITHKLINE,,,,,,Y,,,20200514,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177869051,OT,,,,,,,,,177869051,1,HIV infection
17790761,177907611,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081451,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177907611,OT,,,,,,,,,177907611,1,HIV infection
17790763,177907631,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081450,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177907631,OT,,,,,,,,,177907631,1,HIV infection
17790786,177907861,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081451,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177907861,OT,,,,,,,,,177907861,1,HIV infection
17790789,177907891,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081450,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177907891,OT,,,,,,,,,177907891,1,HIV infection
17790865,177908651,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081452,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177908651,OT,,,,,,,,,177908651,1,HIV infection
17790867,177908671,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081453,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177908671,OT,,,,,,,,,177908671,1,HIV infection
17790893,177908931,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081453,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177908931,OT,,,,,,,,,177908931,1,HIV infection
17790895,177908951,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081456,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177908951,OT,,,,,,,,,177908951,1,HIV infection
17790897,177908971,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081455,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177908971,OT,,,,,,,,,177908971,1,HIV infection
17790900,177909001,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081454,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177909001,OT,,,,,,,,,177909001,1,HIV infection
17790905,177909051,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081452,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177909051,OT,,,,,,,,,177909051,1,HIV infection
17790911,177909111,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081455,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177909111,OT,,,,,,,,,177909111,1,HIV infection
17790913,177909131,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081456,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177909131,OT,,,,,,,,,177909131,1,HIV infection
17790916,177909161,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081454,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177909161,OT,,,,,,,,,177909161,1,HIV infection
17791019,177910191,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081457,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177910191,OT,,,,,,,,,177910191,1,HIV infection
17791021,177910211,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081459,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177910211,OT,,,,,,,,,177910211,1,HIV infection
17791024,177910241,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081458,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177910241,OT,,,,,,,,,177910241,1,HIV infection
17791027,177910271,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081457,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177910271,OT,,,,,,,,,177910271,1,HIV infection
17791029,177910291,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081459,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177910291,OT,,,,,,,,,177910291,1,HIV infection
17791031,177910311,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081458,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,177910311,OT,,,,,,,,,177910311,1,HIV infection
17791156,177911561,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081461,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177911561,OT,,,,,,,,,177911561,1,HIV infection
17791157,177911571,1,I,,20200507,20200515,20200515,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK081460,GLAXOSMITHKLINE,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177911571,OT,,,,,,,,,177911571,1,HIV infection
17791160,177911601,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081460,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177911601,OT,,,,,,,,,177911601,1,HIV infection
17791161,177911611,1,I,,20200507,20200515,20200515,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK081461,VIIV,,,,,,Y,,,20200515,,HP,CN,CN,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,177911611,OT,,,,,,,,,177911611,1,HIV infection
17793320,177933202,2,F,20200507,20200513,20200515,20200526,EXP,,IE-GILEAD-2020-0467150,GILEAD,,,,,M,Y,70.6,KG,20200526,,HP,IE,IE,EFAVIRENZ.,Anaemia;Bladder neoplasm,177933202,HO,,,177933202,1,20200507,,,,177933202,1,HIV infection
17794015,177940151,1,I,20170709,20200507,20200516,20200516,EXP,ES-AEMPS-627943,ES-TEVA-2020-ES-1234796,TEVA,,71,YR,,M,Y,,,20200516,,MD,ES,ES,EFAVIRENZ (1107A),Drug interaction;Upper gastrointestinal haemorrhage,177940151,HO,,,177940151,2,201705,,,,177940151,1,Dyslipidaemia
17794245,177942452,2,F,,20200511,20200515,20200526,EXP,,GB-MYLANLABS-2020M1047882,MYLAN,,,,,M,Y,,,20200526,,CN,GB,GB,EFAVIRENZ.,Suspected COVID-19,177942452,OT,,,,,,,,,177942452,1,Product used for unknown indication
17796602,177966021,1,I,20170709,20200505,20200518,20200518,EXP,ES-AEMPS-627943,ES-GLENMARK PHARMACEUTICALS-2020GMK047722,GLENMARK,,,,,,Y,,,20200518,,HP,ES,ES,EFAVIRENZ.,Upper gastrointestinal haemorrhage,177966021,HO,,,177966021,2,201705,,,,177966021,1,Dyslipidaemia
17798530,177985303,3,F,202003,20200615,20200518,20200617,EXP,,GB-LUPIN HEALTHCARE (UK) LIMITED-2020-02045,LUPIN,,,,A,F,Y,,,20200617,,CN,NL,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,177985303,OT,,,,,,,,,177985303,1,Product used for unknown indication
17799566,177995661,1,I,20050902,20200512,20200518,20200518,EXP,,FR-MYLANLABS-2020M1049691,MYLAN,"ROBERT J. FREERCKSA, USHMA MEHTAB, DAVID F. STEAD, GRAEME A. MEINTJES. HAEMOLYTIC ANAEMIA ASSOCIATED WITH EFAVIRENZ",36,YR,,F,Y,,,20200518,,HP,FR,FR,EFAVIRENZ.,Angioedema;Haematuria;Haemolytic anaemia;Hypersensitivity;Rash,177995661,OT,,,177995661,1,20050510,20191018,,,177995661,1,Product used for unknown indication
17799574,177995741,1,I,,20200512,20200518,20200518,EXP,,IN-MYLANLABS-2020M1049684,MYLAN,"VASA SUSRUTHA, SHUAIB M.A, SOMA SANTOSH KUMAR. EFAVIRENZ INDUCED HAEMOLYTIC ANAEMIA : A RARE CASE REPORT. INDIAN JOURNAL OF BASIC AND APPLIED MEDICAL RESEARCH. 2018;8(1):530-532",38,YR,,F,Y,,,20200518,,HP,IN,IN,EFAVIRENZ.,Haemolytic anaemia,177995741,OT,,,,,,,,,177995741,1,Antiretroviral therapy
17800145,178001451,1,I,,20200514,20200519,20200519,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-038669,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200519,,CN,GB,GB,SUSTIVA,COVID-19,178001451,HO,,,,,,,,,178001451,1,Product used for unknown indication
17801187,178011871,1,I,,20200518,20200519,20200519,EXP,,CA-ROCHE-2603549,ROCHE,,,,,F,Y,,,20200519,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,178011871,DE,,,,,,,,,178011871,1,Product used for unknown indication
17804332,178043322,2,F,20200204,20200529,20200519,20200603,EXP,,UG-009507513-2005UGA005479,MERCK,,30,YR,,F,Y,68,KG,20200603,,CN,UG,UG,EFAVIRENZ.,Drug interaction;Pregnancy with implant contraceptive;Product administration error;Unintended pregnancy,178043322,OT,,,178043322,1,20180213,20200510,,,178043322,1,Contraception
17805044,178050441,1,I,,20200518,20200520,20200520,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-039513,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200520,,CN,GB,GB,EFAVIRENZ.,Suspected COVID-19,178050441,OT,,,,,,,,,178050441,1,Product used for unknown indication
17806738,178067381,1,I,2020,20200513,20200520,20200520,EXP,,GB-GILEAD-2020-0467661,GILEAD,,,,A,M,Y,,,20200520,,CN,GB,GB,EFAVIRENZ.,COVID-19;Kidney infection;Pneumonia,178067381,HO,,,,,,,,,178067381,1,Product used for unknown indication
17808099,178080991,1,I,202003,20200513,20200520,20200520,EXP,,GB-MYLANLABS-2020M1048756,MYLAN,,,,A,M,Y,,,20200520,,CN,GB,GB,EFAVIRENZ.,COVID-19,178080991,OT,,,,,,,,,178080991,1,Product used for unknown indication
17809443,178094431,1,I,,20200513,20200521,20200521,EXP,,GB-AUROBINDO-AUR-APL-2020-025181,AUROBINDO,,,,,M,Y,,,20200521,,CN,GB,GB,EFAVIRENZ.,COVID-19,178094431,OT,,,,,,,,,178094431,1,Product used for unknown indication
17810183,178101831,1,I,,20200509,20200521,20200521,EXP,,CN-GLAXOSMITHKLINE-CN2020APC078974,GLAXOSMITHKLINE,"XIAO Q, XIAO H. STUDY ON IMMUNE RECONSTRUCTION AFTER ANTIRETROVIRAL THERAPY IN HIV / HCV CO-INFECTED PATIENTS. 2020;26(09):1864-1868 DOI:10. 3969 /J.IS",,,,,Y,,,20200521,,MD,CN,CN,EFAVIRENZ.,Nephrolithiasis,178101831,OT,,,,,,,,,178101831,1,HIV infection
17810184,178101841,1,I,,20200509,20200521,20200521,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020APC078974,VIIV,"XIAO Q, XIAO H. STUDY ON IMMUNE RECONSTRUCTION AFTER ANTIRETROVIRAL THERAPY IN HIV / HCV CO-INFECTED PATIENTS. 2020;26(09):1864-1868 DOI:10. 3969 /J.IS",,,,,Y,,,20200521,,MD,CN,CN,EFAVIRENZ.,Nephrolithiasis,178101841,OT,,,,,,,,,178101841,1,HIV infection
17811344,178113441,1,I,20170709,20200513,20200521,20200521,EXP,ES-AEMPS-627943,ES-ACCORD-182420,ACCORD,,71,YR,E,M,Y,,,20200521,,MD,ES,ES,EFAVIRENZ.,Drug interaction;Upper gastrointestinal haemorrhage,178113441,HO,,,178113441,2,200907,,,,178113441,1,Dyslipidaemia
17812978,178129781,1,I,,20200514,20200521,20200521,EXP,,ID-MYLANLABS-2020M1050863,MYLAN,,,,A,,Y,,,20200521,,HP,ID,ID,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Hypothyroidism,178129781,OT,,,,,,,,,178129781,1,Acquired immunodeficiency syndrome
17814152,178141521,1,I,20170709,20200508,20200522,20200522,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-248035,RANBAXY,,71,YR,,M,Y,,,20200522,,HP,NL,ES,EFAVIRENZ.,Upper gastrointestinal haemorrhage,178141521,HO,,,178141521,2,201705,,,,178141521,1,Dyslipidaemia
17814684,178146842,2,F,20200504,20200522,20200522,20200531,EXP,,GB-AUROBINDO-AUR-APL-2020-026015,AUROBINDO,,,,,F,Y,,,20200601,,CN,GB,GB,Efavirenz 600mg,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178146842,OT,,,,,,,,,178146842,1,Product used for unknown indication
17815948,178159481,1,I,202003,20200519,20200522,20200522,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-039753,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20200522,,CN,GB,GB,EFAVIRENZ.,COVID-19,178159481,OT,,,,,,,,,178159481,1,Product used for unknown indication
17817769,178177692,2,F,20200504,20200522,20200522,20200527,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-039766,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200527,,HP,GB,GB,EFAVIRENZ.,COVID-19,178177692,OT,,,,,,,,,178177692,1,Product used for unknown indication
17818786,178187861,1,I,,20200520,20200522,20200522,EXP,,US-GILEAD-2020-0468026,GILEAD,,,,A,M,Y,,,20200522,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal distension;Chromaturia;Intentional product use issue;Jaundice;Malaise;Pruritus;Renal disorder,178187861,OT,,,,,,,,,178187861,1,HIV infection
17820050,178200501,1,I,,20200511,20200525,20200525,EXP,,IN-AUROBINDO-AUR-APL-2020-026172,AUROBINDO,EFAVIRENZ/RETINOL/WARFARIN ACUTE LIVER FAILURE: 4 CASE REPORTS. 2020,35,YR,,F,Y,,,20200525,,HP,IN,IN,EFAVIRENZ.,Acute hepatic failure;Ascites;Hepatomegaly;Jaundice,178200501,HO,,,,,,,,,178200501,1,HIV infection
17822168,178221682,2,F,202003,20200615,20200526,20200626,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-038816,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20200626,,HP,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178221682,OT,,,,,,,,,178221682,1,Product used for unknown indication
17822580,178225801,1,I,,20200520,20200526,20200526,EXP,,US-GILEAD-2020-0468275,GILEAD,,64,YR,A,F,Y,,,20200526,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Liver injury,178225801,OT,,,,,,,,,178225801,1,HIV infection
17822756,178227561,1,I,,20200514,20200526,20200526,EXP,,MY-CIPLA LTD.-2020MY03516,CIPLA,,,,,,Y,,,20200526,,HP,MY,MY,EFAVIR (EFAVIRENZ),Eye swelling;Pruritus;Rash erythematous;Swelling face,178227561,OT,,,,,,,,,178227561,1,Retroviral infection
17826415,178264152,2,F,,20200527,20200527,20200604,EXP,,GB-AUROBINDO-AUR-APL-2020-026045,AUROBINDO,,,,,M,Y,,,20200605,,CN,GB,GB,Efavirenz 600mg,Suspected COVID-19,178264152,OT,,,,,,,,,178264152,1,Product used for unknown indication
17827031,178270311,1,I,,20200514,20200527,20200527,EXP,,MY-CIPLA LTD.-2020MY03520,CIPLA,,,,,,Y,,,20200527,,HP,MY,MY,EFAVIR (EFAVIRENZ),Toxic epidermal necrolysis,178270311,OT,,,,,,,,,178270311,1,Antiretroviral therapy
17827033,178270331,1,I,,20200514,20200527,20200527,EXP,,GB-CIPLA LTD.-2020MY03524,CIPLA,,,,,,Y,,,20200527,,HP,GB,MY,EFAVIR (EFAVIRENZ),Conjunctivitis;Oral candidiasis,178270331,OT,,,,,,,,,178270331,1,Retroviral infection
17827564,178275641,1,I,,20200518,20200527,20200527,EXP,,CA-ROCHE-2603598,ROCHE,,54,YR,,M,Y,,,20200527,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,178275641,OT,,,,,,,,,178275641,1,Bipolar disorder
17827954,178279541,1,I,,20200514,20200527,20200527,EXP,,MY-CIPLA LTD.-2020MY03517,CIPLA,,,,,,Y,,,20200527,,HP,MY,MY,EFAVIR (EFAVIRENZ),Vasculitis,178279541,OT,,,,,,,,,178279541,1,Retroviral infection
17828310,178283102,2,F,202003,20200617,20200527,20200618,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020087892,VIIV,,,,A,F,Y,,,20200618,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178283102,OT,,,,,,,,,178283102,1,Product used for unknown indication
17828328,178283282,2,F,202003,20200617,20200527,20200618,EXP,,GB-GLAXOSMITHKLINE-GB2020087892,GLAXOSMITHKLINE,,,,A,F,Y,,,20200618,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178283282,OT,,,,,,,,,178283282,1,Product used for unknown indication
17830746,178307463,3,F,20200504,20200526,20200527,20200603,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020088452,VIIV,,,,,F,Y,,,20200603,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178307463,OT,,,,,,,,,178307463,1,Product used for unknown indication
17830750,178307503,3,F,20200504,20200526,20200527,20200603,EXP,,GB-GLAXOSMITHKLINE-GB2020088452,GLAXOSMITHKLINE,,,,,F,Y,,,20200603,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178307503,OT,,,,,,,,,178307503,1,Product used for unknown indication
17831133,178311331,1,I,,20200525,20200527,20200527,EXP,,IN-GILEAD-2020-0468883,GILEAD,"JOHN K.J., GUNASEKARAN K., SULTAN N., IYYADURAI R.. CYTOMEGALOVIRUS VENTRICULOENCEPHALITIS PRESENTING WITH HYDROCEPHALUS IN A PATIENT WITH ADVANCED HIV INFECTION. OXFORD MEDICAL CASE REPORTS. 2019;10:443-446. DOI:10.1093/OMCR/OMZ104",38,YR,A,F,Y,,,20200527,,HP,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,178311331,OT,,,,,,,,,178311331,1,HIV infection
17831245,178312451,1,I,20200319,20200525,20200528,20200528,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-041240,BRISTOL MYERS SQUIBB,,72,YR,,M,Y,114,KG,20200527,,PH,GB,GB,EFAVIRENZ.,International normalised ratio increased,178312451,LT,,,178312451,1,20130712,20200501,,,178312451,1,Embolism venous
17834023,178340232,2,F,20200504,20200526,20200528,20200601,EXP,,GB-MYLANLABS-2020M1052007,MYLAN,,,,,F,Y,,,20200601,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178340232,OT,,,,,,,,,178340232,1,Product used for unknown indication
17834941,178349411,1,I,,20200514,20200528,20200528,EXP,,MY-CIPLA LTD.-2020MY03512,CIPLA,,,,,,Y,,,20200528,,HP,MY,MY,EFAVIR (EFAVIRENZ),Skin hyperpigmentation,178349411,OT,,,,,,,,,178349411,1,Antiretroviral therapy
17835784,178357841,1,I,202003,20200504,20200528,20200528,EXP,,GB-MYLANLABS-2020M1045355,MYLAN,,,,A,F,Y,,,20200528,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178357841,OT,,,,,,,,,178357841,1,Product used for unknown indication
17835877,178358771,1,I,201305,20200526,20200528,20200528,EXP,,US-GILEAD-2020-0468908,GILEAD,,61,YR,A,M,Y,,,20200528,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Type 2 diabetes mellitus,178358771,OT,,,178358771,1,201201,201801,,,178358771,1,HIV infection
17839091,178390911,1,I,,20200520,20200529,20200529,EXP,,GB-AUROBINDO-AUR-APL-2020-026312,AUROBINDO,,76,YR,,M,Y,,,20200529,,MD,GB,GB,EFAVIRENZ.,Renal impairment,178390911,OT,,,,,,,,,178390911,1,HIV infection
17840703,178407031,1,I,,20200522,20200529,20200529,EXP,,CA-ROCHE-2607583,ROCHE,,,,,,Y,,,20200529,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,178407031,OT,,,,,,,,,178407031,1,Diffuse large B-cell lymphoma
17840923,178409231,1,I,,20200526,20200529,20200529,EXP,,FR-ABBVIE-20K-056-3418453-00,ABBVIE,,,,,M,Y,3.23,KG,20200529,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,178409231,CA,,,,,,,,,178409231,1,Product used for unknown indication
17841507,178415071,1,I,20050902,20200522,20200529,20200529,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-12-026128",BOEHRINGER INGELHEIM,"ROBERT J. FREERCKSA, USHMA MEHTAB, DAVID F. STEAD, GRAEME A. MEINTJES. HAEMOLYTIC ANAEMIA ASSOCIATED WITH EFAVIRENZ",36,YR,,F,Y,,,20200529,,HP,FR,FR,EFAVIRENZ.,Angioedema;Haematuria;Haemolytic anaemia;Hypersensitivity;Rash,178415071,OT,,,178415071,1,20050510,20191018,,,178415071,1,Product used for unknown indication
17841668,178416681,1,I,,20200525,20200529,20200529,EXP,,GB-MYLANLABS-2020M1051991,MYLAN,,76,YR,,M,Y,,,20200529,,MD,GB,GB,EFAVIRENZ.,Renal impairment,178416681,OT,,,,,,,,,178416681,1,HIV infection
17842933,178429332,2,F,202003,20200615,20200530,20200620,EXP,,GB-AUROBINDO-AUR-APL-2020-024996,AUROBINDO,,,,A,F,Y,,,20200620,,CN,GB,GB,Efavirenz Film-coated Tablet 600mg,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178429332,OT,,,,,,,,,178429332,1,Product used for unknown indication
17843729,178437291,1,I,202003,20200521,20200531,20200531,EXP,,GB-AUROBINDO-AUR-APL-2020-026417,AUROBINDO,,,,,F,Y,,,20200601,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178437291,OT,,,,,,,,,178437291,1,Product used for unknown indication
17845184,178451841,1,I,,20200520,20200601,20200601,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-040119,BRISTOL MYERS SQUIBB,,76,YR,,M,Y,,,20200601,,MD,GB,GB,EFAVIRENZ.,Renal impairment,178451841,OT,,,,,,,,,178451841,1,HIV infection
17847767,178477671,1,I,202003,20200521,20200601,20200601,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-040480,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200601,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178477671,OT,,,,,,,,,178477671,1,Product used for unknown indication
17851391,178513911,1,I,,20200601,20200602,20200602,EXP,,FR-MYLANLABS-2020M1053407,MYLAN,,,,,M,Y,3.23,KG,20200602,,CN,US,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,178513911,OT,,,,,,,,,178513911,1,Product used for unknown indication
17852442,178524421,1,I,20050902,20200520,20200603,20200603,EXP,,FR-AUROBINDO-AUR-APL-2020-026287,AUROBINDO,,36,YR,,F,Y,,,20200603,,HP,FR,FR,EFAVIRENZ.,Angioedema;Haematuria;Haemolytic anaemia;Hypersensitivity;Rash,178524421,OT,,,178524421,2,20050510,20191018,,,178524421,1,Product used for unknown indication
17853450,178534501,1,I,201704,20180125,20200602,20200602,EXP,,FR-BIOVITRUM-2018BV000038,SANOFI AVENTIS,"SATTLER L, RAISSI A, FORNOFF D, GEROUT A, FEUGEAS O, GRUNEBAUM L ET AL.. SWITCHING TOWARD THE USE OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN - STUDY AMONG 30 PATIENTS WITH SEVERE HEMOPHILIA A. ANN BIOL CLIN.. 2020;78(1):35-46",43,YR,,M,Y,62,KG,20200603,,MD,FR,FR,SUSTIVA,Arthralgia;Myalgia,,,,,178534501,1,20170307,,,,178534501,1,Factor VIII deficiency
17853766,178537661,1,I,20200504,20200522,20200603,20200603,EXP,,GB-LUPIN PHARMACEUTICALS INC.-2020-02500,LUPIN,,,,,F,Y,,,20200603,,CN,NL,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,178537661,OT,,,,,,,,,178537661,1,Product used for unknown indication
17859027,178590271,1,I,20200319,20200528,20200604,20200604,EXP,GB-MHRA-EYC 00222768,GB-TEVA-2020-GB-1243390,TEVA,,72,YR,,M,Y,114,KG,20200604,,PH,GB,GB,EFAVIRENZ.,International normalised ratio increased,178590271,LT,,,178590271,1,20130712,20200501,,,178590271,1,Embolism venous
17864160,178641601,1,I,,20200601,20200605,20200605,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-027653",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200605,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,178641601,OT,,,,,,,,,178641601,1,HIV infection
17868370,178683701,1,I,,20200601,20200606,20200606,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-027696",BOEHRINGER INGELHEIM,,45,YR,,M,Y,,,20200606,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,178683701,OT,,,,,,,,,178683701,1,HIV infection
17868459,178684591,1,I,20171006,20200527,20200606,20200606,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2020026669,MACLEODS,,,,,,Y,,,20200606,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,178684591,OT,,,178684591,2,20171006,20180205,,,178684591,1,Product used for unknown indication
17869766,178697662,2,F,,20200526,20200608,20200619,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-041408,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,3.23,KG,20200619,,CN,US,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,178697662,CA,,,,,,,,,178697662,1,Product used for unknown indication
17871565,178715651,1,I,,20200603,20200608,20200608,EXP,,GB-MYLANLABS-2020M1054584,MYLAN,,,,,M,Y,,,20200608,,CN,GB,GB,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",COVID-19;Condition aggravated;Dyspnoea;Fatigue,178715651,OT,,,,,,,,,178715651,1,Product used for unknown indication
17871809,178718092,2,F,,20200608,20200608,20200610,EXP,,BR-PFIZER INC-2020221661,PFIZER,"ANDREOLA, C.. MULTIFOCAL CHOROIDITIS IN DISSEMINATED CRYPTOCOCCUS NEOFORMANS INFECTION. AMERICAN JOURNAL OF OPHTHALMOLOGY. 2006;142 (2):346-348",27,YR,,F,Y,,,20200610,,MD,BR,BR,EFAVIRENZ.,Drug ineffective,178718092,DE,,,,,,,,,178718092,1,Cerebral toxoplasmosis
17872735,178727351,1,I,,20200604,20200608,20200608,EXP,,CA-GILEAD-2020-0470560,GILEAD,,52,YR,A,M,Y,,,20200608,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,178727351,OT,,,,,,,,,178727351,1,HIV infection
17875422,178754221,1,I,201912,20200608,20200609,20200609,EXP,FR-AFSSAPS-AN20200672,FR-ABBVIE-20K-056-3435792-00,ABBVIE,,45,YR,,M,Y,,,20200609,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,178754221,HO,,,178754221,1,20030615,20190228,,,178754221,1,HIV infection
17875895,178758951,1,I,202003,20200608,20200609,20200609,EXP,,US-GILEAD-2020-0470925,GILEAD,,66,YR,A,M,Y,,,20200609,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blindness;Intentional product use issue,178758951,OT,,,,,,,,,178758951,1,HIV infection
17877018,178770181,1,I,,20200605,20200609,20200609,EXP,,GB-MYLANLABS-2020M1055218,MYLAN,,,,,M,Y,,,20200609,,CN,GB,GB,EFAVIRENZ.,SARS-CoV-2 test positive,178770181,OT,,,,,,,,,178770181,1,Product used for unknown indication
17877650,178776501,1,I,,20200605,20200609,20200609,EXP,,NL-GILEAD-2020-0470893,GILEAD,,40,YR,A,M,Y,,,20200609,,MD,NL,NL,EFAVIRENZ.,Migraine,178776501,OT,,,178776501,1,2005,,,,178776501,1,HIV infection
17878630,178786301,1,I,,20200528,20200610,20200610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042255,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20200610,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,178786301,HO,,,,,,,,,178786301,1,HIV infection
17879578,178795781,1,I,,20200528,20200610,20200610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042196,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200610,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,178795781,OT,,,,,,,,,178795781,1,HIV infection
17882173,178821731,1,I,20090119,20200604,20200610,20200610,EXP,,US-ASTRAZENECA-2020SE73671,ASTRAZENECA,,19848,DY,,M,Y,56.7,KG,20200610,,,US,US,SUSTIVA,Chronic kidney disease;Renal failure;Tubulointerstitial nephritis,178821731,OT,,,178821731,1,2013,2018,,,178821731,1,Gastrooesophageal reflux disease
17883746,178837461,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-044933,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837461,OT,,,,,,,,,178837461,1,HIV infection
17883747,178837471,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046213,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837471,OT,,,,,,,,,178837471,1,HIV infection
17883749,178837491,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046197,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837491,OT,,,,,,,,,178837491,1,HIV infection
17883751,178837511,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046198,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837511,OT,,,,,,,,,178837511,1,HIV infection
17883752,178837521,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046196,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178837521,OT,,,,,,,,,178837521,1,HIV infection
17884248,178842481,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046204,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842481,OT,,,,,,,,,178842481,1,HIV infection
17884249,178842491,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046199,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842491,OT,,,,,,,,,178842491,1,HIV infection
17884250,178842501,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046210,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842501,OT,,,,,,,,,178842501,1,HIV infection
17884266,178842661,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046207,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842661,OT,,,,,,,,,178842661,1,HIV infection
17884267,178842671,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046205,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842671,OT,,,,,,,,,178842671,1,HIV infection
17884268,178842681,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046206,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842681,OT,,,,,,,,,178842681,1,HIV infection
17884280,178842801,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046202,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842801,OT,,,,,,,,,178842801,1,HIV infection
17884281,178842811,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046208,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842811,OT,,,,,,,,,178842811,1,HIV infection
17884282,178842821,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046211,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842821,OT,,,,,,,,,178842821,1,HIV infection
17884286,178842861,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046212,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842861,OT,,,,,,,,,178842861,1,HIV infection
17884287,178842871,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046203,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842871,OT,,,,,,,,,178842871,1,HIV infection
17884288,178842881,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046209,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842881,OT,,,,,,,,,178842881,1,HIV infection
17884289,178842891,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046201,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842891,OT,,,,,,,,,178842891,1,HIV infection
17884290,178842901,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046200,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178842901,OT,,,,,,,,,178842901,1,HIV infection
17884526,178845261,1,I,,20200604,20200611,20200611,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020096443,VIIV,,52,YR,,M,Y,,,20200611,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,178845261,OT,,,,,,,,,178845261,1,HIV infection
17884550,178845501,1,I,,20200604,20200611,20200611,EXP,,CA-GLAXOSMITHKLINE-CA2020096443,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20200611,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,178845501,OT,,,,,,,,,178845501,1,HIV infection
17885011,178850111,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046233,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850111,OT,,,,,,,,,178850111,1,HIV infection
17885012,178850121,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046259,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850121,OT,,,,,,,,,178850121,1,HIV infection
17885016,178850161,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046238,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850161,OT,,,,,,,,,178850161,1,HIV infection
17885017,178850171,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046260,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850171,OT,,,,,,,,,178850171,1,HIV infection
17885034,178850341,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046232,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850341,OT,,,,,,,,,178850341,1,HIV infection
17885035,178850351,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046261,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850351,OT,,,,,,,,,178850351,1,HIV infection
17885068,178850681,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046236,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850681,OT,,,,,,,,,178850681,1,HIV infection
17885069,178850691,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046237,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178850691,OT,,,,,,,,,178850691,1,HIV infection
17885152,178851521,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046217,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851521,OT,,,,,,,,,178851521,1,HIV infection
17885153,178851531,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046263,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851531,OT,,,,,,,,,178851531,1,HIV infection
17885156,178851561,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046254,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851561,OT,,,,,,,,,178851561,1,HIV infection
17885157,178851571,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046264,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851571,OT,,,,,,,,,178851571,1,HIV infection
17885158,178851581,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046255,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851581,OT,,,,,,,,,178851581,1,HIV infection
17885159,178851591,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046265,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851591,OT,,,,,,,,,178851591,1,HIV infection
17885160,178851601,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046230,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851601,OT,,,,,,,,,178851601,1,HIV infection
17885161,178851611,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046262,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178851611,OT,,,,,,,,,178851611,1,HIV infection
17885213,178852131,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046229,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852131,OT,,,,,,,,,178852131,1,HIV infection
17885214,178852141,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046258,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852141,OT,,,,,,,,,178852141,1,HIV infection
17885215,178852151,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046270,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852151,OT,,,,,,,,,178852151,1,HIV infection
17885222,178852221,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046266,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852221,OT,,,,,,,,,178852221,1,HIV infection
17885223,178852231,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046231,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852231,OT,,,,,,,,,178852231,1,HIV infection
17885224,178852241,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046256,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852241,OT,,,,,,,,,178852241,1,HIV infection
17885225,178852251,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046223,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852251,OT,,,,,,,,,178852251,1,HIV infection
17885226,178852261,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046219,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852261,OT,,,,,,,,,178852261,1,HIV infection
17885227,178852271,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046272,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852271,OT,,,,,,,,,178852271,1,HIV infection
17885228,178852281,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046228,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852281,OT,,,,,,,,,178852281,1,HIV infection
17885229,178852291,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046273,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852291,OT,,,,,,,,,178852291,1,HIV infection
17885230,178852301,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046214,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852301,OT,,,,,,,,,178852301,1,HIV infection
17885231,178852311,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046216,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852311,OT,,,,,,,,,178852311,1,HIV infection
17885232,178852321,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046218,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852321,OT,,,,,,,,,178852321,1,HIV infection
17885233,178852331,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046268,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852331,OT,,,,,,,,,178852331,1,HIV infection
17885234,178852341,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046227,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852341,OT,,,,,,,,,178852341,1,HIV infection
17885235,178852351,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046267,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852351,OT,,,,,,,,,178852351,1,HIV infection
17885236,178852361,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046271,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852361,OT,,,,,,,,,178852361,1,HIV infection
17885237,178852371,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046220,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852371,OT,,,,,,,,,178852371,1,HIV infection
17885240,178852401,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046225,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852401,OT,,,,,,,,,178852401,1,HIV infection
17885241,178852411,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046222,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852411,OT,,,,,,,,,178852411,1,HIV infection
17885242,178852421,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046226,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852421,OT,,,,,,,,,178852421,1,HIV infection
17885244,178852441,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046235,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852441,OT,,,,,,,,,178852441,1,HIV infection
17885245,178852451,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046269,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852451,OT,,,,,,,,,178852451,1,HIV infection
17885246,178852461,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046257,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852461,OT,,,,,,,,,178852461,1,HIV infection
17885247,178852471,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046221,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852471,OT,,,,,,,,,178852471,1,HIV infection
17885248,178852481,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046224,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852481,OT,,,,,,,,,178852481,1,HIV infection
17885249,178852491,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046215,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852491,OT,,,,,,,,,178852491,1,HIV infection
17885251,178852511,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046234,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178852511,OT,,,,,,,,,178852511,1,HIV infection
17885648,178856481,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046249,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856481,OT,,,,,,,,,178856481,1,HIV infection
17885650,178856501,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046244,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856501,OT,,,,,,,,,178856501,1,HIV infection
17885651,178856511,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046245,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856511,OT,,,,,,,,,178856511,1,HIV infection
17885652,178856521,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046243,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856521,OT,,,,,,,,,178856521,1,HIV infection
17885656,178856561,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046246,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856561,OT,,,,,,,,,178856561,1,HIV infection
17885671,178856711,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046247,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856711,OT,,,,,,,,,178856711,1,HIV infection
17885672,178856721,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046248,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856721,OT,,,,,,,,,178856721,1,HIV infection
17885673,178856731,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046241,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856731,OT,,,,,,,,,178856731,1,HIV infection
17885674,178856741,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046240,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856741,OT,,,,,,,,,178856741,1,HIV infection
17885675,178856751,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046253,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856751,OT,,,,,,,,,178856751,1,HIV infection
17885676,178856761,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046251,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856761,OT,,,,,,,,,178856761,1,HIV infection
17885678,178856781,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046252,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856781,OT,,,,,,,,,178856781,1,HIV infection
17885679,178856791,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046242,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856791,OT,,,,,,,,,178856791,1,HIV infection
17885681,178856811,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046239,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856811,OT,,,,,,,,,178856811,1,HIV infection
17885685,178856851,1,I,,20200601,20200611,20200611,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046250,BRISTOL MYERS SQUIBB,"DE LA FUENTE S, DIAZ-DE SANTIAGO A, VIVAS M, SANCHEZ CHICA E, FOLGUERA C, ANGEL-MORENO A. NEUROTOXICITY RELATED TO EFAVIRENZ DOES NOT PREDICT NEUROTOXICITY RELATED TO DOLUTEGRAVIR. HIV MEDICINE. 2019;20(SUPPL 9):279",,,,,Y,,,20200611,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,178856851,OT,,,,,,,,,178856851,1,HIV infection
17892680,178926802,2,F,2005,20200624,20200612,20200625,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-ABBVIE-20K-130-3440703-00,ABBVIE,,41,YR,,F,Y,,,20200625,,MD,PT,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,178926802,OT,,,178926802,1,2005,2005,,,178926802,1,Product used for unknown indication
17893622,178936221,1,I,20180712,20180907,20200615,20200615,EXP,,FR-CADILA HEALTHCARE LIMITED-FR-ZYDUS-029990,ZYDUS PHARM,,,,,,Y,,,20200615,,PH,FR,FR,EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR DISOPROXIL,Lactic acidosis;Metabolic acidosis;Renal failure;Septic shock;Urinary tract infection,178936221,HO,,,178936221,1,20180414,20180713,,,178936221,1,Diabetes mellitus
17893955,178939552,2,F,,20200612,20200615,20200618,EXP,,FR-AUROBINDO-AUR-APL-2020-028781,AUROBINDO,GREGOIRE M. LES INTERACTIONS M?DICAMENTEUSES CHEZ LE PATIENT ?G? VIVANT AVEC LE VIH. LA LETTRE DU PHARMACOLOGUE. 2020;34(1-2):12-6,64,YR,,F,Y,,,20200619,,MD,FR,FR,Efavirenz;Emtricitabine;Tenofovir disoproxil fumarate,Cushing's syndrome;Drug interaction,178939552,OT,,,,,,,,,178939552,1,HIV infection
17894471,178944711,1,I,2017,20200605,20200615,20200615,EXP,,PT-AUROBINDO-AUR-APL-2020-028611,AUROBINDO,,45,YR,,M,Y,,,20200615,,MD,PT,PT,EFAVIRENZ+EMTRICITABINE+TENOFOVIR FILM COATED TABLETS,Acute myocardial infarction;Blood creatinine abnormal;Cardiac failure acute;Cardiorenal syndrome;Dyslipidaemia;Headache;Hepatic function abnormal;Insomnia;Renal disorder;Renal impairment,178944711,OT,,,178944711,1,2011,2017,,,178944711,1,HIV infection
17895204,178952041,1,I,,20200601,20200615,20200615,EXP,,MY-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-044929,BRISTOL MYERS SQUIBB,"KOH KC, IBRAHIM NM, ONG SCL. PARADOXICAL WORSENING OF CHEST RADIOGRAPHS SECONDARY TO IMMUNE RECONSTITUTION SYNDROME (IRIS) IN A PATIENT WITH ADVANCED HIV INFECTION AND RHODOCOCCUS PNEUMONIA. MEDICAL JOURNAL OF MALAYSIA. 2020;75(2):164-6",36,YR,,M,Y,,,20200615,,MD,MY,MY,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Pneumonia bacterial,178952041,OT,,,,,,,,,178952041,1,HIV infection
17896699,178966991,1,I,,20200615,20200615,20200615,EXP,,CA-ROCHE-2621904,ROCHE,,54,YR,,M,Y,,,20200615,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,178966991,DE,,,,,,,,,178966991,1,Bipolar disorder
17898801,178988011,1,I,20190724,20200610,20200615,20200615,EXP,,ZA-GILEAD-2020-0472264,GILEAD,,22,YR,A,F,Y,,,20200615,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,178988011,OT,,,178988011,1,20180319,,,,178988011,1,HIV infection
17901651,179016511,1,I,,20200602,20200616,20200616,EXP,,AR-GLAXOSMITHKLINE-AR2020GSK095608,GLAXOSMITHKLINE,"TORRADO LE, FREIRE A, MARTINEZ M, VIEITES A, BERGADA I, LOPEZ EL ET AL. EXOGENOUS CUSHING SYNDROME DUE TO DRUG INTERACTION OF RITONAVIR AND INHALED FLUTICASONE. REPORT OF THREE PEDIATRIC CASES. ARCHIVOS ARGENTINOS DE PEDIATRIA. 2020;118 (3):E278-E283",13,YR,,M,Y,,,20200616,,MD,AR,AR,EFAVIRENZ.,Adrenal suppression;Blood corticotrophin decreased;Cortisol decreased;Cushing's syndrome;Cushingoid;Drug interaction;Hypertrichosis;Nose deformity;Skin striae;Weight increased,179016511,OT,,,,,,,,,179016511,1,Idiopathic interstitial pneumonia
17902632,179026321,1,I,201912,20200608,20200617,20200617,EXP,,FR-AUROBINDO-AUR-APL-2020-029010,AUROBINDO,,45,YR,,M,Y,,,20200617,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179026321,HO,,,179026321,1,20070115,20160420,,,179026321,1,HIV infection
17902750,179027501,1,I,201912,20200610,20200616,20200616,EXP,FR-AFSSAPS-AN20200672,FR-JNJFOC-20200617185,JOHNSON AND JOHNSON,,45,YR,,M,Y,,,20200616,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179027501,HO,,,179027501,1,20181018,20190228,,,179027501,1,HIV infection
17902855,179028551,1,I,20050813,20200611,20200616,20200616,EXP,FR-GILEAD-2009-0020445,NVSC2020FR164261,NOVARTIS,,,,,F,Y,1.19,KG,20200616,,MD,FR,FR,SUSTIVA,Anencephaly;Arnold-Chiari malformation;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Foetal malformation;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,179028551,OT,,,179028551,2,20050908,20050908,,,179028551,1,Foetal exposure during pregnancy
17903519,179035192,2,F,20191201,20200615,20200616,20200625,EXP,,FR-SA-2020SA153932,SANOFI AVENTIS,,,,,,Y,,,20200625,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179035192,OT,,,179035192,1,20130101,20160420,,,179035192,1,Factor IX deficiency
17909424,179094241,1,I,,20200609,20200617,20200617,EXP,,MY-MYLANLABS-2020M1057062,MYLAN,"KOH KC, IBRAHIM NM, ONG SCL. PARADOXICAL WORSENING OF CHEST RADIOGRAPHS SECONDARY TO IMMUNE RECONSTITUTION SYNDROME (IRIS) IN A PATIENT WITH ADVANCED HIV INFECTION AND RHODOCOCCUS PNEUMONIA. MED-J-MALAYSIA 2020;75(2):164-166.",38,YR,,M,Y,,,20200617,,MD,MY,MY,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,179094241,OT,,,,,,,,,179094241,1,HIV infection
17910829,179108292,2,F,,20200617,20200618,20200622,EXP,,MY-AUROBINDO-AUR-APL-2020-030085,AUROBINDO,,38,YR,,M,Y,,,20200622,,HP,MY,MY,EFAVIRENZ.,Atelectasis;Condition aggravated;Immune reconstitution inflammatory syndrome,179108292,OT,,,,,,,,,179108292,1,HIV infection
17913197,179131971,1,I,,20200615,20200618,20200618,EXP,,US-GILEAD-2020-0473214,GILEAD,"RAVIMOHAN S, AULD S.C, MAENETJE P, RATSELA N, MLOTSHWA M, NCUBE I, SMITH J.P, VANGU M.-D.-T, SEBE M, KOSSENKOV A, WEISSMAN D, WALLIS R.S, CHURCHYARD G, KORNFELD H. BISSON G.P.. LUNG INJURY ON ANTIRETROVIRAL THERAPY IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS/TUBERCULOSIS.. CLINICAL INFECTIOUS DISEASES. 2020;70 (9):1845-1854. DOI:10.1093/CID/CIZ560",,,A,,Y,,,20200618,,MD,US,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dyspnoea;Immune reconstitution inflammatory syndrome associated tuberculosis;Pleural effusion,179131971,OT,,,,,,,,,179131971,1,HIV infection
17913215,179132151,1,I,,20200615,20200618,20200618,EXP,,US-GILEAD-2020-0473215,GILEAD,"RAVIMOHAN S, AULD S.C, MAENETJE P, RATSELA N, MLOTSHWA M, NCUBE I, SMITH J.P, VANGU M.-D.-T, SEBE M, KOSSENKOV A, WEISSMAN D, WALLIS R.S, CHURCHYARD G, KORNFELD H. BISSON G.P.. LUNG INJURY ON ANTIRETROVIRAL THERAPY IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS/TUBERCULOSIS.. CLINICAL INFECTIOUS DISEASES. 2020;70 (9):1845-1854. DOI:10.1093/CID/CIZ560",,,A,,Y,,,20200618,,MD,US,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal lymphadenopathy;Immune reconstitution inflammatory syndrome associated tuberculosis;Intestinal obstruction,179132151,OT,,,,,,,,,179132151,1,HIV infection
17913217,179132171,1,I,,20200615,20200618,20200618,EXP,,US-GILEAD-2020-0473216,GILEAD,"RAVIMOHAN S, AULD S.C, MAENETJE P, RATSELA N, MLOTSHWA M, NCUBE I, SMITH J.P, VANGU M.-D.-T, SEBE M, KOSSENKOV A, WEISSMAN D, WALLIS R.S, CHURCHYARD G, KORNFELD H. BISSON G.P.. LUNG INJURY ON ANTIRETROVIRAL THERAPY IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS/TUBERCULOSIS. CLINICAL INFECTIOUS DISEASES. 2020;70 (9):845-1854. DOI:10.1093/CID/CIZ560",,,A,,Y,,,20200618,,MD,US,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenopathy,179132171,OT,,,,,,,,,179132171,1,HIV infection
17914713,179147131,1,I,201912,20200611,20200618,20200618,EXP,FR-AFSSAPS-AN20200672,FR-GILEAD-2020-0473012,GILEAD,,45,YR,A,M,Y,,,20200618,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179147131,HO,,,179147131,1,20070115,20181018,,,179147131,1,HIV infection
17915734,179157341,1,I,,20200611,20200619,20200619,EXP,,GB-AUROBINDO-AUR-APL-2020-029588,AUROBINDO,,,,,M,Y,,,20200619,,CN,GB,GB,Efavirenz 600mg,SARS-CoV-2 test positive,179157341,OT,,,,,,,,,179157341,1,Product used for unknown indication
17915851,179158511,1,I,,20200608,20200619,20200619,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-045409,BRISTOL MYERS SQUIBB,,64,YR,,F,Y,,,20200619,,HP,FR,FR,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE,Cushing's syndrome;Labelled drug-drug interaction medication error,179158511,OT,,,,,,,,,179158511,1,HIV infection
17916419,179164191,1,I,201912,20200608,20200619,20200619,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-045454,BRISTOL MYERS SQUIBB,,45,YR,,M,Y,,,20200619,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179164191,OT,,,179164191,1,20070115,20160420,,,179164191,1,HIV infection
17917426,179174261,1,I,201912,20200612,20200619,20200619,EXP,FR-AFSSAPS-AN20200672,FR-009507513-2006FRA004674,MERCK,,45,YR,,M,Y,,,20200619,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179174261,HO,,,179174261,1,20070911,20160210,,,179174261,1,HIV infection
17917928,179179281,1,I,2005,20200615,20200619,20200619,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-VIIV HEALTHCARE LIMITED-PT2020101740,VIIV,,41,YR,,F,Y,,,20200619,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179179281,OT,,,179179281,1,2003,2005,,,179179281,1,Antiretroviral therapy
17917940,179179401,1,I,2005,20200615,20200619,20200619,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-GLAXOSMITHKLINE-PT2020101740,GLAXOSMITHKLINE,,41,YR,,F,Y,,,20200619,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179179401,OT,,,179179401,1,2003,2005,,,179179401,1,Antiretroviral therapy
17919334,179193341,1,I,201802,20200609,20200619,20200619,EXP,,US-ELI_LILLY_AND_COMPANY-US202006008681,ELI LILLY AND CO,"LERNER J, MICHEL M, DASANU C.RELAPSED REFRACTORY METASTATIC SQUAMOUS CELL CANCER OF ANAL CANAL IN A PATIENT WITH RETROVIRAL INFECTION RESPONDING TO CETUXIMAB.JOURNAL OF ONCOLOGY PHARMACY PRACTICE 2020;26(4):1025-1028.DOI:10.1177/1078155219884605",62,YR,,M,Y,,,20200619,,HP,US,US,EFAVIRENZ.,Cardio-respiratory arrest;Right ventricular failure,179193341,DE,,,179193341,1,201709,201802,,,179193341,1,Anal cancer metastatic
17923272,179232721,1,I,201912,20200614,20200622,20200622,EXP,FR-AFSSAPS-AN20200672,FR-TEVA-2020-FR-1788963,TEVA,,45,YR,,M,Y,,,20200622,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179232721,HO,,,179232721,1,20020615,20181018,,,179232721,1,HIV infection
17924500,179245001,1,I,,20200612,20200622,20200622,EXP,,CA-ROCHE-2621283,ROCHE,,52,YR,,M,Y,,,20200622,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,179245001,OT,,,,,,,,,179245001,1,HIV infection
17924752,179247521,1,I,,20200615,20200622,20200622,EXP,,CA-ROCHE-2622430,ROCHE,,45,YR,,M,Y,,,20200622,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,179247521,OT,,,,,,,,,179247521,1,HIV infection
17924753,179247531,1,I,,20200615,20200622,20200622,EXP,,CA-ROCHE-2622329,ROCHE,,,,,M,Y,,,20200622,,HP,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,179247531,OT,,,,,,,,,179247531,1,Product used for unknown indication
17925970,179259701,1,I,201912,20200612,20200622,20200622,EXP,FR-AFSSAPS-AN20200672,FR-MYLANLABS-2020M1056848,MYLAN,,45,YR,,M,Y,,,20200622,,MD,FR,FR,EFAVIRENZ.,Congestive cardiomyopathy,179259701,HO,,,179259701,1,20020615,20181018,,,179259701,1,HIV infection
17929857,179298571,1,I,201611,20200616,20200623,20200623,EXP,,NVSC2020US169617,NOVARTIS,"LERNER J, MICHEL M, DASANU CA. RELAPSED REFRACTORY METASTATIC SQUAMOUS CELL CANCER OF ANAL CANAL IN A PATIENT WITH RETROVIRAL INFECTION RESPONDING TO CETUXIMAB. JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2020;26(4):1025-8",62,YR,,M,Y,,,20200623,,HP,US,US,EFAVIRENZ.,Pancytopenia;Product use in unapproved indication;Therapy partial responder,179298571,OT,,,,,,,,,179298571,1,Anal squamous cell carcinoma
17930673,179306731,1,I,,20200612,20200623,20200623,EXP,,CA-ROCHE-2621256,ROCHE,,52,YR,,M,Y,,,20200623,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,179306731,OT,,,,,,,,,179306731,1,HIV infection
17933676,179336761,1,I,2005,20200616,20200624,20200624,EXP,PT-EMA-DD-20200610-BHARDWAJ_R-142802,PT-TEVA-2020-PT-1790166,TEVA,,41,YR,,F,Y,,,20200624,,MD,PT,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,179336761,OT,,,179336761,1,2005,2006,,,179336761,1,Antiretroviral therapy
17941077,179410771,1,I,,20200611,20200624,20200624,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-046767,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200624,,CN,GB,GB,EFAVIRENZ.,Asymptomatic COVID-19,179410771,OT,,,,,,,,,179410771,1,Product used for unknown indication
17941267,179412671,1,I,201908,20200619,20200624,20200624,EXP,,US-GILEAD-2020-0475282,GILEAD,,59,YR,A,M,Y,,,20200624,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Eye disorder,179412671,HO,,,179412671,1,201806,201806,,,179412671,1,HIV infection
17945994,179459941,1,I,,20200618,20200626,20200626,EXP,E2B_02979508,CA-ACCORD-186584,ACCORD,,,,,M,Y,,,20200626,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,179459941,HO,,,,,,,,,179459941,1,Product used for unknown indication
17949208,179492081,1,I,,20200618,20200626,20200626,EXP,,CA-ROCHE-2625977,ROCHE,,,,,,Y,,,20200626,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,179492081,OT,,,,,,,,,179492081,1,Diffuse large B-cell lymphoma
17949727,179497271,1,I,,20200618,20200626,20200626,EXP,E2B_02966351,CA-ACCORD-186554,ACCORD,,54,YR,,M,Y,,,20200626,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,179497271,OT,,,,,,,,,179497271,1,Bipolar disorder
17951505,179515051,1,I,202003,20200526,20200626,20200626,EXP,,GB-TEVA-2020-GB-1242462,TEVA,,,,A,F,Y,,,20200626,,CN,GB,GB,EFAVIRENZ.,Asthenia;COVID-19;Cough;Dyspnoea;Oropharyngeal pain;Vomiting,179515051,OT,,,,,,,,,179515051,1,Product used for unknown indication
17953178,179531781,1,I,20170709,20200622,20200627,20200627,EXP,ES-AEMPS-627943,NVSC2020ES176146,NOVARTIS,,71,YR,,M,Y,,,20200628,,HP,ES,ES,EFAVIRENZ.,Upper gastrointestinal haemorrhage,179531781,HO,,,179531781,2,200907,,,,179531781,1,Dyslipidaemia
17954859,179548591,1,I,,20200618,20200629,20200629,EXP,,CA-AUROBINDO-AUR-APL-2020-030609,AUROBINDO,,54,YR,,M,Y,,,20200629,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,179548591,OT,,,,,,,,,179548591,1,HIV infection
17957689,179576891,1,I,202003,20200618,20200629,20200629,EXP,,GB-MYLANLABS-2020M1058698,MYLAN,,,,A,F,Y,,,20200629,,CN,GB,GB,EFAVIRENZ.,Abdominal pain upper;COVID-19;Cough;Diarrhoea;Dyspnoea;Pyrexia;Tremor,179576891,OT,,,,,,,,,179576891,1,Product used for unknown indication
6049025,604902519,19,F,20050813,20200430,20060519,20200511,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13375589,BRISTOL MYERS SQUIBB,,24,YR,,F,Y,56,KG,20200511,,CN,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,604902519,OT,,,604902519,1,20050513,20050908,,,604902519,1,HIV infection
6049849,60498492,2,F,20050902,20200520,20060522,20200602,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13378054,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20200602,,HP,ZA,ZA,EFAVIRENZ.,Autoimmune haemolytic anaemia,60498492,OT,,,60498492,1,20050801,2005,,,60498492,1,HIV infection
6927324,69273248,8,F,20050813,20200401,20090304,20200407,EXP,,FR-GILEAD-2009-0020445,GILEAD,,,,,F,Y,1.19,KG,20200407,,MD,FR,FR,SUSTIVA,Anencephaly;Arnold-Chiari malformation;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Foetal malformation;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,69273248,DE,,,69273248,1,20050523,20060216,,,69273248,1,HIV infection
6927327,69273276,6,F,20050813,20200401,20090304,20200407,EXP,,FR-GILEAD-2009-0020444,GILEAD,,25,YR,A,F,Y,56,KG,20200407,,HP,FR,FR,SUSTIVA,Abortion induced;Insomnia;Maternal exposure during pregnancy;Vertigo,69273276,HO,,,69273276,1,20050523,20050908,,,69273276,1,HIV infection
7155921,715592113,13,F,,20200427,20091022,20200501,EXP,,CA-ROCHE-663583,ROCHE,"PFEFFER G, PFEFFER G, COTE H, MONTANER J, LI C, JITRATKOSOL M AND MEZEI M. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY 2009 JUL 07;73 (1):71-72.",52,YR,,M,Y,,,20200501,,MD,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,715592113,OT,,,,,,,,,715592113,1,HIV infection
7573291,75732912,2,F,20100626,20200628,20100903,20200630,EXP,,PHHY2010FR55335,NOVARTIS,,80,YR,,M,Y,73,KG,20200630,,HP,FR,FR,SUSTIVA,Acute coronary syndrome;Aortic arteriosclerosis;Blood triglycerides increased;C-reactive protein increased;Carotid artery stenosis;Chest pain;Dyspnoea exertional;Haematoma;Headache;Hypertrophic cardiomyopathy;Intermittent claudication;Myocardial infarction;Troponin increased,75732912,HO,,,75732912,2,20170105,20170512,,,75732912,1,Product used for unknown indication
8260766,826076612,12,F,2006,20200430,20111123,20200511,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15921299,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200511,,CN,FR,FR,SUSTIVA,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,826076612,OT,,,826076612,1,20050513,20050908,,,826076612,1,Product used for unknown indication
9115540,91155402,2,F,2005,20200616,20130225,20200622,EXP,,PT-MERCK-1302PRT004051,MERCK,,41,YR,,F,Y,,,20200622,,CN,US,PT,EFAVIRENZ.,Drug intolerance;Drug resistance;Fatigue;Hepatic cirrhosis;Hypertension;Nausea;Vomiting,91155402,OT,,,91155402,1,2005,2006,,,91155402,2,Antiretroviral therapy
9415152,94151523,3,F,,20200615,20130723,20200619,EXP,,CA-ROCHE-1251186,ROCHE,,,,,M,Y,,,20200619,,HP,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,94151523,OT,,,,,,,,,94151523,1,Product used for unknown indication
